

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094468 A2

(51) International Patent Classification⁷: **C07K 14/315**

Strasse 50, 65929 Frankfurt (DE). **FLODGAARD, Hans**
[DK/DK]; Melvillevej 6, DK-2900 Hellerup (DK).

(21) International Application Number:
PCT/EP2004/004429

(74) Agents: **ROQUES, Sarah, Elizabeth et al.**; J.A. Kemp &
Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(22) International Filing Date: 23 April 2004 (23.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0309246.7 23 April 2003 (23.04.2003) GB
0329112.7 16 December 2003 (16.12.2003) GB

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **HANSA MEDICAL RESEARCH AB** [SE/SE]; Edison Park, S-223 69 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BJÖRCK, Lars** [SE/SE]; Magle Stora Kyrkogata 10, S-223 50 Lund (SE). **HERWALD, Heiko** [DE/SE]; Kyrkogatan 8, S-24014 Veberöd (SE). **MÖRGELIN, Matthias** [SE/SE]; Tre Högars Väg 26B, S-224 75 Lund (SE). **RUSSELL, Wayne** [GB/SE]; Hallandsgatan 7, S-224 32 Kävlinge (SE). **NORRBY-TEGLUND, Anna** [SE/SE]; Gustavslundsvägen 19, S-144 63 Rönninge (SE). **LINDBOM, Lennart** [SE/SE]; Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm (SE). **SOLLENBERG, Ulla** [SE/SE]; Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm (SE). **CRAMER, Henning** [DE/DE]; Ludwigshafener

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHOD AND TREATMENT**

(57) Abstract: A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated β_2 integrin or a functional variant thereof; (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and (e) determining whether the test substance inhibits the interaction between the components; thereby to determine whether a test substance is an anti-streptococcal agent.



WO 2004/094468 A2

Field of the Invention

The invention relates to methods for identifying anti-streptococcal agents. The invention also relates to the use of such agents in the treatment of streptococcal infections.

Background to the Invention

Streptococcus pyogenes is one of the most common and important human bacterial pathogens. It causes relatively mild infections such as pharyngitis (strep throat) and impetigo, but also serious clinical conditions like rheumatic fever, post-streptococcal glomerulonephritis, necrotizing fasciitis, septicemia, and streptococcal toxic shock syndrome (STSS). Increases in the number of life-threatening systemic *S. pyogenes* infections have been reported worldwide since the late 1980s, and have attracted considerable attention and concern.

S. pyogenes expresses substantial amounts of M protein, α -helical coiled-coil surface proteins. M protein is a clinical virulence determinant of *S. pyogenes* which promotes the survival of the bacterium in human blood. Apart from being associated with the bacterial cell wall, M protein is also released from the surface by the action of a cysteine proteinase secreted by the bacteria.

Polymorphonuclear neutrophils (PMNs) are part of the first line of defence against bacterial infections. The recruitment of these cells from the bloodstream to an inflamed site involves their recognition of inflammatory mediators, their interaction with adhesion molecules of the vascular endothelium, and, finally, their migration across the endothelial barrier to the site of infection where PMNs phagocytize invading bacteria. Under physiological conditions non-activated PMNs circulate in the bloodstream. However, once activated by a chemotactic signal, they become adherent and begin to roll on the endothelium towards the site of infection, where they attach firmly to the endothelium and start to extravasate into the infected tissue. These adhesion processes involve the sequential up- and down-regulation of a number of different adhesion molecules both on PMNs and the endothelium, including integrins. Activated PMNs also release heparin-

binding protein (HBP) from its intracellular storage. HBP is an inflammatory mediator that induces vascular leakage.

Summary of the Invention

5 The present inventors have shown that interactions between streptococcal M protein-fibrinogen complexes and β_2 integrins of PMNs cause activation of PMNs and release of heparin binding protein (HBP), thereby causing an inflammatory response. This interaction presents a novel target for the identification of anti-streptococcal agents, which can be used to block the interaction between streptococcal M protein-fibrinogen
10 complexes and β_2 integrins thus preventing the activation of PMNs and therefore blocking the inflammatory response that would otherwise result.

In accordance with the present invention, there is thus provided a method for identifying an anti-streptococcal agent, which method comprises:

- 15 (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof;
 - (b) providing, as a second component, isolated fibrinogen or a functional variant thereof;
 - (c) providing, as a third component, an isolated β_2 integrin or a functional variant thereof;
 - 20 (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and
 - (e) determining whether the test substance inhibits the interaction between the components;
- thereby to determine whether a test substance is an anti-streptococcal agent.

25 The invention also provides:

- a method for identifying an anti-streptococcal agent, which method comprises:
 - (a) providing, as a first component, a streptococcal M protein or a functional
variant thereof;
 - (b) providing, as a second component, fibrinogen or a functional variant
30 thereof;

- (c) providing, as a third component, one or more polymorphonuclear neutrophils (PMNs);
- (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and
- 5 (e) monitoring any inhibition of the activation of PMNs; thereby to determine whether a test substance is an anti-streptococcal agent;
- a test kit suitable for use in identifying a test substance which is capable of inhibiting the interaction between a streptococcal M protein or a functional variant thereof, fibrinogen and a functional variant thereof and a β_2 integrin or a functional
- 10 variant thereof, which kit comprises:
- (a) an isolated streptococcal M protein or a functional variant thereof;
- (b) isolated fibrinogen or a functional variant thereof; and
- (c) an isolated β_2 integrin or a functional variant thereof;
- a test kit suitable for use in identifying a test substance which is
- 15 capable of inhibiting the interaction between a streptococcal M protein or a functional variant thereof, fibrinogen or a functional variant thereof and PMNs, which kit comprises:
- (a) a streptococcal M protein or a functional variant thereof;
- (b) fibrinogen or a functional variant thereof; and
- (c) one or more PMNs;
- 20 - an anti-streptococcal agent identified by a method of the invention;
- an anti-streptococcal agent identified by a method of the invention for use in a method of treatment of the human or animal body by therapy;
- use of an integrin antagonist in the manufacture of a medicament for the treatment of a streptococcal infection;
- 25 - use of an inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin in the manufacture of a medicament for the treatment of a streptococcal infection;
- use of an agent identified by a method of the invention in the manufacture of a medicament for the treatment of a streptococcal infection;

- a method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an agent identified by a method of the invention to a said individual;
- a method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an integrin antagonist to a said individual;
- a method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin to a said individual;
- a pharmaceutical composition comprising an inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin identified by a method of the invention and a pharmaceutically acceptable carrier or diluent;
- a method for providing a pharmaceutical composition, which method comprises:
 - (a) identifying an agent that inhibits the interaction between streptococcal M protein, fibrinogen and β_2 integrin by a method of the invention; and
 - (b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent;
- a method of treating an individual suffering from a streptococcal infection, which method comprises:
 - (c) identifying an agent that inhibits the interaction between streptococcal M protein, fibrinogen and β_2 integrin by a method of the invention; and
 - (d) administering a therapeutically effective amount of the inhibitor thus identified to a said individual.

Brief description of the drawings

Figure 1 shows the release of HBP in human blood. *Panel A*: Human blood was incubated with M1 protein, protein H, SpeB, protein SIC, fMLP, lipoteichoic acid (LTA), or hyaluronic acid (HA) for 30 min at 37°C. Cells were pelleted and the concentration of HBP in the supernatants was determined by ELISA. The total amount of HBP in blood was determined by lysing cells with Triton X-100, and the amount of HBP released after

incubation without stimulation for 30 min at 37°C was considered as background. The figure presents the mean \pm SD of three independently performed experiments, each done in duplicate. *Panel B*: Human blood was stimulated with M1 protein, M1 protein fragments A-S and S-C3 (schematically depicted at the top), or protein H for 30 min at 37°C. Cells were pelleted and the concentration of HBP in the supernatants was determined by ELISA. The figure presents the mean \pm SD of three independently performed experiments, each done in duplicate. *Panel C*: Serial dilutions of supernatants from overnight cultures of strains AP1 and MC25, or growth medium alone were added to human blood and the release of HBP was determined.

Figure 2 shows the inhibition of M1 protein-induced release of HBP in human blood. Human blood was incubated with tBoc (100 μ M), pertussis toxin (1 μ g/ml), genistein (100 μ M), wortmannin (0,2 μ M), BAPTAM/EGTA (10 μ M/1 mM), EGTA (1 mM), AG1478 (2 μ M), GF109203 (2 μ M), H-89 (1 μ M), PD98059 (20 μ M), or U-73122 (10 μ M) in the presence or absence of M1 protein (1 μ g/ml) for 30 min at 37°C. Cells were centrifuged and the concentration of HBP in the supernatants was determined by ELISA. The results are expressed as percent of released HBP in the presence of inhibitor relative to release of HBP in the absence of inhibitor (100%). The figure presents the mean \pm SD of three independently performed experiments, each done in duplicate.

Figure 3 shows that M1 protein-induced release of HBP correlates with M1 protein-induced precipitation of plasma proteins. *Panel A*: Samples of 10% human plasma in PBS (1 ml) were incubated with 125 I-M1 protein (10^5 cpm/ml, approximately 1 ng) in the presence (0.01 μ g/ml, 0.1 μ g/ml, 0.2 μ g/ml, 1 μ g/ml, and 10 μ g/ml) or absence of non-labeled M1 protein for 30 min at 37°C. Samples were centrifuged and the radioactivity of the pellets was measured. Results are presented as percentage of added total radioactivity and the figure shows the mean \pm SD of three independent experiments, each done in duplicate. *Panel B*: Human whole blood was treated with M1 protein (0.01 μ g/ml, 0.1 μ g/ml, 0.2 μ g/ml, 1 μ g/ml, or 10 μ g/ml) for 30 min at 37°C. Cells were centrifuged and the amount of HBP in the supernatants was determined. *Panel C*: One ml samples of human plasma (10% in PBS) or fibrinogen (300 μ g/ml in PBS) were incubated with 125 I-M1 protein (10^5 cpm/ml, approximately 1 ng) in the absence or presence of non-labeled

M1 protein (0.01 µg/ml, 0.1 µg/ml, 0.2 µg/ml, 1 µg/ml, or 10 µg/ml). After 30 min of incubation at 37°C, samples were centrifuged and the radioactivity of the pellets was measured. Results are presented as percentage of total radioactivity. The figure presents the mean ± SD of three independent experiments, each done in duplicate.

5 Figure 4 shows that M1 protein-induced precipitates formed in a fibrinogen solution or in plasma cause HBP release. M1 protein (1 µg/ml) was added to 10% human plasma or fibrinogen (300 µg/ml) in PBS for 30 min. After a centrifugation step, the resulting pellets were resuspended and incubated with 10% human blood diluted in PBS for 30 min followed by the measurement of released HBP. Plasma or fibrinogen solutions devoid of
10 M1 protein were treated in the same way and served as negative controls. The figure presents the mean ± SD of four independently performed experiments.

Figure 5 shows inhibition of the M1 protein-induced HBP release by fibrinogen derived peptides and antibodies to CD18. *Panel A:* Human plasma was incubated with peptides Gly-Pro-Arg-Pro, Gly-His-Arg-Pro (100 µg/ml), or buffer alone for 15 min at
15 37°C. Clotting was initiated by the addition of thrombin and the clotting time was determined. *Panel B:* M1 protein was added to whole human blood (1 µg/ml) followed by the addition of different amounts of Gly-Pro-Arg-Pro, Gly-His-Arg-Pro, antibody mAB IB4 to CD18, or antibody AS88 (directed against human H-kininogen). After 30 min of incubation at 37°C, cells were centrifuged and the amount of HBP in the supernatants was
20 determined. Data are expressed as percent of HBP release induced by M1 protein alone, and the bars represent means ± SD of 3 experiments, each done in duplicate.

Brief description of the Sequence Listing

SEQ ID NO: 1 shows the amino acid sequence of the M1 protein of *Streptococcus*
25 *pyogenes* (NCBI Accession Number NP_269973).

SEQ ID NO: 2 shows the amino acid sequence of a peptide derived from the NH₂-terminal region of fibrinogen.

SEQ ID NO: 3 shows the amino acid sequence of a second peptide derived from the NH₂-terminal region of fibrinogen.

30 SEQ ID NO: 4 is a RT-PCR primer used in the Example.

SEQ ID NO: 5 shows the amino acid sequence of the human fibrinogen α chain isoform α preproprotein (NCBI Accession Number NP_068657).

SEQ ID NO: 6 shows the amino acid sequence of the human fibrinogen β chain precursor (NCBI Accession Number P02675).

5 SEQ ID NO: 7 shows the amino acid sequence of the human fibrinogen γ chain isoform γ -B precursor (NCBI Accession Number NP_068656).

SEQ ID NO: 8 shows the amino acid sequence of human integrin α_M chain precursor (NCBI Accession Number NP_000623).

10 SEQ ID NO: 9 shows the amino acid sequence of human integrin α subunit (α_X chain) precursor (NCBI Accession Number AAA51620).

SEQ ID NO: 10 shows the amino acid sequence of human β_2 integrin chain precursor (NCBI Accession Number NP_000202).

Detailed Description of the Invention

15 The invention provides methods for identifying an anti-streptococcal agent. A suitable method of the invention consists essentially of:

- contacting (i) an isolated streptococcal M protein or a functional variant thereof, (ii) isolated fibrinogen or a functional variant thereof, and (iii) an isolated β_2 integrin or a functional variant thereof with a test substance under conditions that would permit the
- 20 components to interact in the absence of the test substance; and
- determining whether the test substance is capable of inhibiting the interaction between the components.

It can then be readily determined whether the test substance is an anti-streptococcal agent.

25 An isolated streptococcal M protein or a functional variant thereof is provided as a first component. Streptococcal M proteins and M-like proteins are well known. There are more than 80 different streptococcal M proteins. The M protein of the invention may be, for instance, M1, M3, M11, M12 or M28. The M protein is preferably M1 or M3. Typically, the M protein is derived from *S. pyogenes*. Preferably, the M protein is M1

30 protein of *S. pyogenes*. The amino acid sequence of the M1 protein of *S. pyogenes* is set out in SEQ ID NO: 1.

A functional variant of a streptococcal M protein maintains the ability to form a complex with fibrinogen. Such a complex is capable of binding to a β_2 integrin. The functional variant may be a fragment of a streptococcal M protein. A functional variant of a streptococcal M protein typically binds specifically to fibrinogen. Binding of M
5 proteins to fibrinogen may be analysed as described by Åkesson et al. (Åkesson et al., 1994, Biochem. J., 300, 877-886). The affinity constant for the interaction between a functional variant of a streptococcal M protein and fibrinogen is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

10 Typically, the binding affinity for fibrinogen of such a functional variant is substantially the same as that of the wild type M protein. Alternatively, the binding affinity for fibrinogen may be greater or less than that of the wild type streptococcal M protein. For example, a functional variant may have a binding affinity for fibrinogen which is at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, or at least
15 70% of that of the wild type streptococcal M protein. Alternatively, the binding affinity for fibrinogen of the functional variant may be at least 105%, at least 110%, at least 120%, or at least 130% of that of the wild type streptococcal M protein. For instance, the binding affinity for fibrinogen of a functional variant of a streptococcal M protein may be from 95% to 105%, from 90% to 110%, from 85% to 120%, from 80% to 130%, from
20 75% to 140% or from 70% to 150% of that of the wild type. In each case, the affinity constant for the interaction between a functional variant of a streptococcal M protein and fibrinogen is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

A functional variant of a streptococcal M protein may be a polypeptide which has
25 a sequence similar to that of an M protein such as the wild type M1 protein of *S. pyogenes* of SEQ ID NO: 1. Thus a functional variant will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to that of the streptococcal M protein calculated over the full length of those sequences. The UWGCG Package provides the BESTFIT program which can be used to calculate
30 identity (for example used on its default settings) (Devereux *et al* (1984) Nucleic Acids Research 12, 387-395). The PILEUP and BLAST algorithms can alternatively be used to

calculate identity or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S. F. *et al* (1990) J Mol Biol 215:403-10. Identity may therefore be calculated using the UWGCG package, using the BESTFIT program on its default settings. Alternatively, sequence identity can
5 be calculated using the PILEUP or BLAST algorithms. BLAST may be used on its default settings.

Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying
10 short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each
15 sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X
20 determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two
25 sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum
30 probability in comparison of the first sequence to the second sequence is less than about 1,

preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A functional variant may be a modified version of a streptococcal M protein such as the *S. pyogenes* M1 protein with the amino acid sequence of SEQ ID NO: 1. The sequence of the modified version is different to that of the wild type M protein. The modified version of a wild type M protein may have, for example, amino acid substitutions, deletions or additions. At least 1, at least 2, at least 3, at least 5, at least 10 or at least 20 amino acid substitutions or deletions; for example, may be made, up to a maximum of 100 or 50 or 30. For example, from 1 to 100, from 2 to 50, from 3 to 30, or from 5 to 15 amino acid substitutions or deletions may be made. Typically, if substitutions are made, the substitutions will be conservative substitutions, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other. Deletions are preferably deletions of amino acids from one or both ends of the sequence of the streptococcal M protein. Alternatively, deletions are of regions not involved in the interaction with fibrinogen. For example, the deletion may be in the S-C3 fragment of *S. pyogenes* M1 protein.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

The streptococcal M protein or a functional variant thereof may be fused to an additional heterologous polypeptide sequence to produce a fusion polypeptide. Thus,

additional amino acid residues may be provided at, for example, one or both termini of the streptococcal M protein or a functional variant thereof. The additional sequence may perform any known function. Typically, it may be added for the purpose of providing a carrier polypeptide, by which the streptococcal M protein or functional variant thereof can be, for example, affixed to a label, solid matrix or carrier. Thus the first component for use in the invention may be in the form of a fusion polypeptide which comprises heterologous sequences. Indeed, in practice it may often be convenient to use fusion polypeptides. This is because fusion polypeptides may be easily and cheaply produced in recombinant cell lines, for example recombinant bacterial or insect cell lines. Fusion polypeptides may be expressed at higher levels than the wild-type streptococcal M protein or functional variant thereof. Typically this is due to increased translation of the encoding RNA or decreased degradation. In addition, fusion polypeptides may be easy to identify and isolate. Typically, fusion polypeptides will comprise a polypeptide sequence as described above and a carrier or linker sequence. The carrier or linker sequence will typically be derived from a non-human, preferably a non-mammalian source, for example a bacterial source. This is to minimize the occurrence of non-specific interactions between heterologous sequences in the fusion polypeptide and fibrinogen, which is the target of the structural M protein or functional variant thereof.

The streptococcal M protein or a functional variant thereof may be modified by, for example, addition of histidine residues, a T7 tag or glutathione S-transferase, to assist in its isolation. Alternatively, the heterologous sequence may, for example, promote secretion of the streptococcal M protein or functional variant thereof from a cell or target its expression to a particular subcellular location, such as the cell membrane. Amino acid carriers can be from 1 to 400 amino acids in length or more typically from 5 to 200 residues in length. The M protein or functional variant thereof may be linked to a carrier polypeptide directly or via an intervening linker sequence. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic acid or aspartic acid.

Streptococcal M proteins or functional variants thereof may be chemically modified, for example, post-translationally modified. For example they may comprise modified amino acid residues or may be glycosylated. They can be in a variety of forms of polypeptide derivatives, including amides and conjugates with polypeptides.

Chemically modified streptococcal M proteins or functional variants thereof also include those having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized side groups include those which have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups and formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine.

Also included as chemically modified streptococcal M proteins or functional variants thereof are those which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may be substituted for proline or homoserine may be substituted for serine.

A streptococcal M protein or a functional variant thereof and/or other polypeptides used as part of a first component may carry a revealing label. Suitable labels include radioisotopes such as ^{125}I , ^{32}P or ^{35}S , fluorescent labels, enzyme labels, or other protein labels such as biotin.

The second component comprises isolated fibrinogen or a functional variant thereof. Fibrinogen is a soluble plasma protein which is converted to insoluble fibrin in the blood by the action of the enzyme thrombin. This contributes to the formation of a blood clot. Fibrinogen is composed of six peptide chains. These are arranged in two identical subunits, each composed of an $\text{A}\alpha$, a $\text{B}\beta$ and a γ chain, joined by disulphide bonds. Streptococcal M protein binds to fibrinogen (Kantor, 1965, J. Exp. Med., 121, 849-859) with high affinity (Åkesson et al., 1994, Biochem. J., 300, 877-886; Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Fibrinogen also binds to PMNs via β_2 integrins (Altieri, 1999, Thromb. Haemost., 82, 781-786). The binding site for the β_2 integrin Mac1 has been mapped to the N-terminal region of the $\text{A}\alpha$ chain of fibrinogen. In addition, the unique sequence KQAGDV, which is found at the C-terminal end of the γ chain, is essential for integrin binding.

A functional variant of fibrinogen maintains the ability to bind to and thus form a complex with a streptococcal M protein. Such a complex is then capable of binding to a

β_2 integrin. The functional variant of fibrinogen typically shows substantially specific binding to a streptococcal M protein. The affinity constant for the interaction between a functional variant of fibrinogen and a streptococcal M protein is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

Typically, the binding affinity of a functional variant of fibrinogen for a streptococcal M protein is substantially the same as that of wild type fibrinogen. Alternatively, the binding affinity for the streptococcal M protein may be greater or less than that of wild type fibrinogen. For example, a functional variant of fibrinogen may have a binding affinity for streptococcal M protein which is at least 95%, at least 90%, at least 85%, at least 80%, at least 75% or at least 70% of that of wild type fibrinogen. Alternatively, the binding affinity for the streptococcal M protein of the functional variant may be at least 105%, at least 110%, at least 120% or at least 130% of that of wild type fibrinogen. For example, the binding affinity for streptococcal M protein of the functional variant may be from 95% to 105%, from 90% to 110%, from 85% to 120%, from 80% to 130%, from 75% to 140% or from 70% to 150% of that of wild type fibrinogen. In each case, typically the affinity constant for the interaction between a functional variant of fibrinogen and a streptococcal M protein is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

A functional variant of fibrinogen may contain an A α chain which has a sequence similar to that of the native A α chain of fibrinogen, such as the human A α chain shown in SEQ ID NO: 5. A functional variant of fibrinogen may contain a B β chain which has a sequence similar to that of the native B β chain, for example the human B β chain shown in SEQ ID NO: 6. A functional variant of fibrinogen may contain a γ chain whose sequence is similar to that of the native γ chain such as the human γ chain of SEQ ID NO: 7. An A α , B β or γ chain can therefore have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to that of the native A α , B β or γ chain of fibrinogen, such as the human A α , B β or γ chains shown in SEQ ID NOs 5 to 7, calculated over the full length of those sequences. However, the chains must still be capable of assembly into a functional molecule. Sequence identity can be calculated

using the methods described above. The BESTFIT program of the UWGCG package may be used on its default settings. Alternatively the PILEUP or BLAST algorithms may be used on their default settings.

A functional variant may be a modified version of fibrinogen which may have, for example, amino acid substitutions, deletions or additions in the A α and/or the B β and/or the γ chains of fibrinogen. Such substitutions, deletions or additions may be made, for example, to the sequences of the human A α , B β or γ chains shown in SEQ ID NOs 5 to 7. Any combination of chains or all of the chains may be modified. However, any deletions, additions or substitutions must still allow the A α , B β and γ chains of fibrinogen to assemble into a functional molecule. At least 1, at least 2, at least 3, at least 5, at least 10, at least 20 or at least 50 amino acid substitutions or deletions, for example, may be made up to a maximum of 70 or 50 or 30 in each chain. For example, from 1 to 70, from 2 to 50, from 3 to 30 or from 5 to 20 amino acid substitutions or deletions may be made. Typically, if substitutions are made, the substitutions will be conservative substitutions as described above. Deletions are preferably deletions of amino acids from one or both ends of the sequence of the A α , B β or γ chains of fibrinogen such as those shown in SEQ ID NOs 5 to 7. Alternatively, deletions are of regions not involved with the interaction with streptococcal M proteins.

Any of the polypeptide chains of fibrinogen or a functional variant thereof may be fused to an additional heterologous polypeptide sequence to produce a fusion polypeptide, as long as the polypeptide chains are still capable of assembling into a functional molecule. Such a fusion polypeptide may be a carrier polypeptide or contain a linker sequence. Such polypeptides are described above.

The polypeptide chains of fibrinogen or a functional variant thereof may be chemically modified as described above. Alternatively the polypeptide chains of fibrinogen or a functional variant thereof may carry a revealing label. Suitable labels are described above.

The third component comprises an isolated β_2 integrin or a functional variant thereof. Integrins are a large family of heterodimeric cell surface adhesion receptors, composed of a β chain and an α chain. Each subunit is composed of a large extracellular domain, a single transmembrane domain and a short cytoplasmic domain. A number of α

and β subunits have been identified and these can associate in a restricted manner. An α subunit usually only associates with a particular β subunit but β subunits are more promiscuous. β_2 integrins are the most abundant integrins expressed by PMNs. Four different α chains (α_M , α_L , α_X and α_D) can associate with the β_2 chain. Of these, $\alpha_M\beta_2$, also known as CD11b/CD18, and $\alpha_X\beta_2$, also known as CD11c/CD18, are the main integrins expressed on PMNs. These are the receptors for fibrinogen.

A functional variant of a β_2 integrin maintains the ability to bind to a streptococcal M protein-fibrinogen complex. A functional variant of a β_2 integrin typically binds specifically to streptococcal M protein-fibrinogen complex. The affinity constant for the interaction between a functional variant of a β_2 integrin and streptococcal M protein-fibrinogen complex is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

Typically, the binding affinity of a functional variant of a β_2 integrin for a streptococcal M protein-fibrinogen complex is substantially the same as that of the wild type β_2 integrin. Alternatively, the binding affinity for streptococcal M protein-fibrinogen complexes may be greater or less than that of the wild type β_2 integrin. For example, the binding affinity of the functional variant of the β_2 integrin for streptococcal M protein-fibrinogen complexes may be at least 95%, at least 90%, at least 85%, at least 80%, at least 75% or at least 70% of that of the wild type β_2 integrin. Alternatively, the binding affinity of the functional variant may be at least 110%, at least 120%, or at least 130% of that of the wild type β_2 integrin. For instance, the binding affinity for streptococcal M protein-fibrinogen complexes of the functional variant may be from 70% to 160%, from 75% to 150%, from 80% to 140%, from 85% to 130%, from 90% to 120% or from 95% to 110% of that of the wild type β_2 integrin. In each case, typically the affinity constant for the interaction between a functional variant of a β_2 integrin and streptococcal M protein-fibrinogen complex is typically from 1×10^{-6} M to 1×10^{-12} M. For example, the affinity constant may be from 1×10^{-7} M to 1×10^{-11} M or from 1×10^{-8} M to 1×10^{-10} M.

A functional variant of a β_2 integrin may contain an α and/or a β_2 chain which has a sequence similar to that of either the native α or the native β_2 chain of a β_2 integrin. For example, the α chain may have a sequence similar to that of the human α_M chain shown in

SEQ ID NO: 8 or to that of the human α_X chain shown in SEQ ID NO: 9. The β_2 chain may have a sequence similar to that of the human β_2 chain shown in SEQ ID NO: 10.

Thus an α and/or a β_2 chain can therefore have at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to

that of the native α or β_2 chain, such as those of SEQ ID NOs 8 to 10, calculated over the full length of those sequences. Again, sequence identity can be calculated using any of the packages described above. The BESTFIT program of the UWGCG package may be used on its default settings. Alternatively, the PILEUP or BLAST algorithms may be used on their default settings.

A functional variant of a β_2 integrin may be a modified version of a β_2 integrin which has, for example, amino acid substitutions, deletions or additions in either or both of the α and β_2 chains. For example, the α_M , α_X or β_2 chains may contain substitutions, deletions or additions to the sequence of the native α_M , α_X or β_2 chain such as those of the human α_M , α_X and β_2 chains shown in SEQ ID NOs 8 to 10. At least 1, at least 2, at least 5, at least 10, at least 30, at least 50 or at least 100 amino acid substitutions or deletions, for example, may be made, up to a maximum of 200, 100, 50 or 30 in either or both of the α and β_2 chains. For example, from 1 to 200, from 2 to 150, from 3 to 100, from 5 to 50 or from 10 to 30 amino acid substitutions or deletions may be made. Typically, any substitutions will be conservative substitutions as described above. Deletions are preferably deletions of amino acids from one or both ends of the sequence of the α or β_2 chain such as any of the sequences of SEQ ID NOs 8 to 10. Alternatively, deletions are of regions not involved in the interaction with streptococcal M protein-fibrinogen complexes.

The α or β_2 chain of a β_2 integrin or a functional variant thereof may be fused to a heterologous polypeptide sequence to produce a fusion polypeptide. This may produce a carrier polypeptide, as described above. Alternatively, the α or β_2 chain of a β_2 integrin or functional variant thereof may be modified by, for example, addition of amino acid residues to assist in its isolation. It may be linked to a carrier polypeptide directly or via a linker sequence. The α or β_2 chain of a β_2 integrin or functional variant thereof may be

chemically modified as described above, or it may be carry a revealing label. Suitable labels are described above.

The method of the invention can be carried out according to any suitable protocol. Preferably, the method is adapted so that it can be carried out in a single reaction vessel
5 such as a single well of a plastic microtiter plate and thus can be adapted for high throughput screening. Preferably, therefore, the assay is an *in vitro* assay.

A streptococcal M protein or a functional variant thereof and/or other polypeptides used as part of a first component may be expressed using recombinant DNA techniques. For example, suitable polypeptides may be expressed in, for example,
10 bacterial or insect cell lines (see, for example, Munger *et al.*, 1998, Molecular Biology of the Cell, 9, 2627-2638). Typically, a recombinant streptococcal M protein can be produced by expression in *E. coli*. The M protein is preferably *S. pyogenes* M1 protein. Recombinant polypeptides are produced by providing a polynucleotide encoding a streptococcal M protein or functional variant thereof. Such polynucleotides are provided
15 with suitable control elements, such as promoter sequences, and provided in expression vectors and the like for expression of streptococcal M protein or a functional variant thereof. Suitable polypeptides may be isolated biochemically from any suitable bacteria.

Alternatively, M protein can be obtained from streptococcal cells that express M proteins endogenously or through the use of recombinant techniques. For example, an M
20 protein from *S. pyogenes* may be produced by treating *S. pyogenes* cells with a protease. The M protein is preferably M1 protein. The protease may be endogenous to *S. pyogenes*, for example the *S. pyogenes* cysteine proteinase SpeB. Alternatively, the protease may be derived from PMNs. Typically, the PMN protease is produced by lysing PMNs. A protease may also be produced recombinantly. M protein may alternatively be obtained
25 by expression of a truncated version of the M protein which lacks the membrane spanning region (Collin and Olsén, 2000, Mol. Microbiol., 36, 1306-1318). Such a protein may be expressed in *S. pyogenes* or *E. coli* and will be secreted by the bacteria without the need for proteolytic cleavage.

Alternatively, a streptococcal M protein or a functional variant thereof may be
30 chemically synthesized. Synthetic techniques, such as a solid-phase Merrifield-type synthesis, may be preferred for reasons of purity, antigenic specificity, freedom from

unwanted side products and ease of production. Suitable techniques for solid-phase peptide synthesis are well known to those skilled in the art (see for example, Merrifield *et al.*, 1969, *Adv. Enzymol* 32, 221-96 and Fields *et al.*, 1990, *Int. J. Peptide Protein Res*, 35, 161-214). In general, solid-phase synthesis methods comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain.

Fibrinogen or a functional variant thereof may be produced by recombinant methods such as expression in bacterial or insect cell lines as described above.

Alternatively, fibrinogen or a functional variant thereof may be chemically synthesized.

10 Fibrinogen may be isolated from human blood, preferably from human plasma.

The streptococcal M protein or a functional variant thereof may be provided in association with fibrinogen or a functional variant thereof. That is to say, a complex of streptococcal M protein or a functional variant thereof and fibrinogen or a functional variant thereof can be used in the invention. Such a complex will be capable of binding to β_2 integrins. Alternatively, the streptococcal M protein or functional variant thereof and fibrinogen or functional thereof may be provided separately.

A β_2 integrin or a functional variant thereof may be produced by recombinant methods or be chemically synthesized as described above. The β_2 integrin may be isolated from PMN lysate.

20 The streptococcal M protein, fibrinogen and β_2 integrin used in the method described above are provided in substantially isolated form. That is to say that the streptococcal M protein, fibrinogen and β_2 integrin or functional variant of any of these may be produced as described above and then isolated. They will generally comprise at least 80%, for instance at least 90%, 95% or 99% by weight of the dry mass in the preparation.

Streptococcal M protein and/or fibrinogen and/or β_2 integrin used in the invention may be present in non-naturally occurring form. The streptococcal M protein and/or fibrinogen and/or β_2 integrin may be in substantially purified form.

An alternative method of the invention consists essentially of:

30 - contacting (i) a streptococcal M protein or a functional variant thereof, (ii)

fibrinogen or a functional variant thereof, and (iii) one or more polymorphonuclear neutrophils (PMNs) with a test substance under conditions that would permit the components to interact in the absence of the test substance; and

- monitoring any inhibition of the activation of PMNs.

5 It can there be readily determined whether the test substance is an anti-streptococcal agent.

The first component, streptococcal M protein or functional variant thereof, and the second component, fibrinogen or a functional variant thereof, may be provided by any of the methods described above. The PMNs may be provided in human blood. The
10 streptococcal M protein and fibrinogen bind to the PMNs via β_2 integrins on the surface of the PMNs.

In a typical method of the invention, isolated streptococcal M protein, isolated fibrinogen and isolated β_2 integrin are mixed together. A test substance is then added to the mixture under conditions that would permit the components to interact in the absence
15 of the test substance. Suitable conditions can be identified by mixing together the isolated streptococcal M protein, isolated fibrinogen and isolated β_2 integrin in the absence of the test substance to determine whether the components interact in the absence of the test substance, for example by determining whether the components form aggregates in the
20 absence of the test substance. Such aggregates can be detected by electron microscopy. Alternatively, radiolabelled proteins can be used to spike the reaction mixture and the amount of radioactivity in the aggregates can be used to quantify the formation of aggregates.

In an alternative method of the invention, PMNs are reconstituted with a mixture of streptococcal M protein and plasma (to provide fibrinogen). A test substance is then
25 added to the mixture under conditions that would permit the components to interact in the absence of the test substance. Suitable conditions can be identified by reconstituting the PMNs with a mixture of streptococcal M protein and plasma in the absence of the test substance and determining whether the components form aggregates or whether the PMNs are activated in the absence of the test substance. The activation of PMNs is
30 typically determined by monitoring the release of HBP.

A cell adhesion assay may alternatively be carried out. In a typical cell adhesion assay, streptococcal M protein-fibrinogen complexes formed from isolated M protein and isolated fibrinogen are coated onto the walls of the suitable vessel, in particular the well of a plastic microtiter plate. In one suitable assay format, the third component β_2 integrin, produced, for example, chemically or recombinantly and then isolated is simply added to the assay vessel along with a test substance. Binding of the β_2 integrin to the M protein-fibrinogen complex can be followed by the use of β_2 integrin which carries a label, for example a radioactive label or a fluorescent label.

Alternatively, in another suitable assay format, PMN cells are added to the vessel and allowed to interact with streptococcal M protein-fibrinogen complexes in the presence of a test product. These complexes may be formed simply by mixing streptococcal M protein with fibrinogen. The number of cells which bind to the M protein-fibrinogen complex is then determined. This may be carried out by, for example, staining the cells and then carrying out spectrophotometry. Optionally, the stain may be eluted and the spectrophotometry carried out on the eluted sample.

In an alternative assay of the invention, M protein-fibrinogen complexes are coated on the walls of the suitable vessel and then PMN cells are added to the vessel and allowed to interact with the M protein-fibrinogen complexes in the presence of a test product. Inhibition of binding between the M protein-fibrinogen complexes and PMNs is then detected by monitoring the activation of the PMNs. Typically, this can be done by measuring the release of heparin binding protein (HBP). A preferred method of the present invention comprises providing *S.pyogenes*, fibrinogen and PMNs with a test substance to test, as in the assay described above, whether the test substance inhibits binding of the M protein-fibrinogen complexes to β_2 integrin on the surface of the PMNs.

Suitable methods of the invention may be carried out in the presence of suitable buffers.

Suitable control experiments may be carried out. For example, assays may be carried out in the absence of a test substance to monitor the interaction between M protein-fibrinogen complexes and isolated β_2 integrin or PMNs.

Suitable test substances which can be tested in the above methods include combinatorial libraries, defined chemical entities, peptide and peptide mimetics,

oligonucleotides and natural product libraries, such as display (e.g. phage display libraries) and antibody products. For example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and humanized antibodies may be used. The antibody may be an intact immunoglobulin molecule or a fragment thereof such as a Fab, F(ab')₂ or Fv fragment. Suitable peptides include the peptide with the sequence GPRP. Suitable antibodies include antibodies directed against the B-repeats of *S. pyogenes* M1 protein, the monoclonal antibody IB4 and antibodies to CD11c.

Suitable test substances also include integrin antagonists, typically β_2 integrin antagonists. Suitable integrin antagonists include anti-integrin antibodies, peptide mimetics and non-peptide mimetics. Anti-integrin antibodies may be of any of the types of antibodies described above. Antagonists can be identified by testing whether they inhibit the action of an agonist which, in the absence of the antagonist, would otherwise bind to the receptor and exert a biological effect.

Typically, organic molecules will be screened, preferably small organic molecules which have a molecular weight of from 50 to 2500 daltons. Candidate products can be biomolecules including saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

Test substances may be used in an initial screen of, for example, 10 substances per reaction, and the substances of these batches which show inhibition tested individually. Test substances may be used at a concentration of from 1nM to 1000 μ M, preferably from 1 μ M to 100 μ M, more preferably from 1 μ M to 10 μ M.

An inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin is one which produces a measurable reduction in such an interaction in a method described above. An inhibitor of the interaction is one which causes the degree of interaction to be reduced or substantially eliminated, as compared to the degree of interaction in the absence of that inhibitor. Preferred inhibitors are those which inhibit the

interaction by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of 1 μgml^{-1} , 10 μgml^{-1} , 100 μgml^{-1} , 500 μgml^{-1} , 1 mgml^{-1} , 10 mgml^{-1} , 100 mg ml^{-1} . The percentage inhibition represents the percentage decrease in any interaction between streptococcal M protein, fibrinogen and β_2 integrin in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition and concentration of inhibitor may be used to define an inhibitor of the invention, with greater inhibition at lower concentrations being preferred. Test substances which show activity in methods of the invention can be tested in *in vivo* systems, such as an animal disease model. Thus, candidate inhibitors could be tested for their ability to attenuate inflammation and/or lung lesions caused by streptococci in mice. Thus it can be determined whether test substances identified by methods of the invention are effective anti-streptococcal agents.

Inhibitors of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% by weight of the dry mass in the preparation. The product is typically substantially free of other cellular components. The product may be used in such a substantially isolated, purified or free form in the method of the invention.

The invention also provides test kits. A suitable kit consists essentially of an isolated streptococcal M protein or a functional variant thereof, isolated fibrinogen or a functional variant thereof, and an isolated β_2 integrin or a functional variant thereof. An alternative kit of the invention consists essentially of a streptococcal M protein or a functional variant thereof, fibrinogen or a functional variant thereof, and one or more PMNs. The test kit may also comprise means for determining whether a test substance disrupts the interaction between the components. Such a means may be the reagents and solutions required to determine whether streptococcal M proteins, fibrinogen and β_2 integrin or PMNs interact according to any method known in the art. A test kit of the invention may also comprise one or more buffers. Kits of the invention are optionally provided with packaging and preferably comprise instructions for the use of the kit.

Inhibitors of the invention may be used in a method of treatment of the human or animal body by therapy. In particular, inhibitors of the present invention may be used in

the treatment of streptococcal infections, preferably in the treatment of infection by *S. pyogenes*. Inhibitors can be used to improve the condition of a patient suffering from a streptococcal infection. Such inhibitors may be used in the treatment of humans or animals. Such inhibitors may be used in prophylactic treatment, for example, in
5 immunosuppressed patients more susceptible to streptococcal infection. Alternatively, such agents may be used in patients demonstrated to have a streptococcal infection to alleviate the symptoms thereof. A therapeutically effective amount of inhibitor may be given to a host in need thereof.

The inhibitors may be administered in a variety of dosage forms. Thus, they can
10 be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. They may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. They may also be administered as suppositories. A physician will be able to determine the required route of administration for each
15 particular patient.

The formulation of an inhibitor for use in preventing or treating streptococcal infection will depend upon factors such as the nature of the exact substance, whether a
2 pharmaceutical or veterinary use is intended, etc. An inhibitor may be formulated for simultaneous, separate or sequential use.

20 An inhibitor is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium
25 or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances
30 used in pharmaceutical formulations. Such pharmaceutical preparations may be

manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose
5 with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive
10 oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

15 A therapeutically effective amount of an inhibitor is administered to an individual in need thereof. The dose of the inhibitor may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for
20 any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific substance, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

The following Example illustrates the invention:

25

Example

Materials and Methods

Reagents. Neutrophil Isolation Medium (NIM) was purchased from Cardinal Associates Inc. (Santa Fe, NM). RPMI 1640 medium with Glutamax I (trade mark),
30 Minimum Essential Medium (MEM) with Earle's salts and L-glutamine, fetal bovine serum, and penicillin (5000 units/ml) / streptomycin (5000 µg/ml) solution were

purchased from Life Technologies (Täby, Sweden). Ionomycin and formyl-methionyl-leucyl-phenylalanine (fMLP) were obtained from Calbiochem (La Jolla, CA). The acetoxymethyl ester of N,N'-(1,2-ethanediylbis(oxy-2,1-phenylene))bis(N-(carboxymethyl)) (BAPTA), and ProLong[®] Antifade Kit were from Molecular Probes (Eugene, OR). 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) was from Merck (Whitehouse Station, NJ). Streptococcal cysteine proteinase (SpeB) zymogen was purified from the medium of AP1 bacteria by ammonium sulfate precipitation (80 % w/v) followed by fractionation on S-Sepharose (Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Recombinant M1 protein, fragments A-S and S-C3, and protein H were obtained by expression in *E. coli* and purified as described earlier (Åkesson et al., 1994, Biochem. J., 300, 877-886; Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Recombinant human HBP was produced using the baculovirus expression system in Sf9 insect cells (Invitrogen Corp., Carlsbad, California) and was purified as described (Laemmli, 1970, Nature, 227, 680-685). Lipoteichoic acid (LTA), hyaluronic acid (HA), and bovine serum albumin (BSA) were from Sigma Chemical Co. (St. Louis, MO). Mouse mAB 2F23C3 and rabbit antiserum (409A) to recombinant HBP were prepared and purified as described earlier (Lindmark et al., J. Leukoc. Biol., 66, 634-643) and peroxidase-conjugated goat anti-rabbit IgG was from Bio-Rad Laboratories (Richmond, CA). Peptides H-2935 (Gly-Pro-Arg-Pro) and H-2940 (Gly-His-Arg-Pro) were purchased from Bachem Feinchemikalien AG (Bubendorf, Switzerland). Fluanison/fentanyl and midazolam were from Janssen Pharmaceutica, Beers, Belgium and Hoffman-La Roche, Basel, Switzerland.

Cell culture, neutrophil isolation, and stimulation of cells. Human PMNs were isolated from fresh heparinized blood of healthy volunteers using NIM, a single step density gradient medium, according to the instructions supplied by the manufacture. PMNs were counted with a hemocytometer, resuspended in MEM medium at 10^7 cells/ml and maintained on rotation in this medium at room temperature until use. All experiments on isolated PMNs were performed in Na-medium and initiated within 1 h of PMN isolation. Neutrophilic proteinase release was induced by PMN activation through antibody cross-linking of CD11b/CD18 as described previously (Gautam et al., 2000, J. Exp. Med., 191, 1829-1839).

Bacterial strains. *S. pyogenes* strain AP1 used in this study is the 40/58 strain from the World Health Organization Collaborating Centre for references and Research on Streptococci, Institute of Hygiene and Epidemiology, Prague, Czech Republic. Its protein binding properties have been described (Åkesson et al., 1990, Immunol., 27, 523-531; Åkesson et al., 1994, Biochem. J., 300, 877-886; Gomi et al., 1990, J. Immunol., v. 144, p. 4046-4052). The MC25 strain, an AP1 mutant strain, devoid of surface-associated M1 protein, was generated as described earlier (Collin and Olsén, 2000, Mol. Microbiol., 36, 1306-1318).

Enzymatic treatment of S. pyogenes. *S. pyogenes* bacteria (strain AP1) were grown in Todd-Hewitt broth (Difco, Detroit, MI) at 37°C for 16 h and harvested by centrifugation at 3000 x g for 20 min. The bacteria were washed twice in PBS and resuspended in PBS to 2 x 10⁹ cells/ml. Various amounts of secretion products from PMNs were added to bacterial suspensions followed by incubation for 2 h at 37°C. Bacteria were spun down at 3000 x g for 20 min, and the resulting pellets and supernatants were saved. Digestions were terminated by addition of SDS sample buffer reducing conditions.

SDS-polyacrylamide gel electrophoresis, Western blotting, and immunoprinting. Proteins were separated by 12.5% (w/v) polyacrylamide gel electrophoresis in the presence of 1% (w/v) SDS (Laemmli, 1970, Nature, 227, 680-685). Molecular weight markers were from Sigma Chemical Co. (St. Louis, MO). The resolved proteins were visualized by the silver stain technique. Proteins were also transferred onto nitrocellulose membranes for 30 min at 100 mA (Khyse-Andersen, 1984, J. Biochem. Biophys. Methods, 10, 203-209). The membranes were blocked with PBS containing 5% (w/v) dry milk powder and 0.05% (w/v) Tween-20, pH 7.4. Immunoprinting of the transferred proteins was done according to Towbin *et al.* (Towbin et al., 1979, Proc. Natl. Acad. Sci. USA, 76, 4350-4354). Polyclonal antibodies against M1 protein, diluted 1:50000 in the blocking buffer, was used. Bound antibodies were detected using a peroxidase-conjugated secondary antibodies against rabbit IgG (dilution 1:3000) followed by a chemiluminescence detection method. Alternatively, membranes were blocked, incubated with fibrinogen (2 µg/ml) followed by immunodetection with antibodies to fibrinogen (1:1000) and peroxidase-conjugated secondary antibodies against rabbit immunoglobulin (1:3000 diluted).

HBP release. 100 µl human blood were diluted in PBS to a final volume of 1.0 ml and incubated with various PMNs-activating components for 30 min at 37°C. Cells were centrifuged (300 x g for 15 min) and the supernatant was analyzed by sandwich ELISA. In order to quantify the total amount of HBP in blood, cells were lysed with 0.02% (v/v) Triton X-100, and pelleted as described above.

Determination of HBP. The concentration of HBP in neutrophilic exudates was determined by a sandwich ELISA (Tapper et al., 2002, Blood, 99, 1785-1793). The ELISA was found to be highly specific showing no crossreactivity with elastase, cathepsin G, or proteinase 3.

Precipitation assay. Radiolabeled M1 protein (¹²⁵I-M1 protein). 10,000 cpm was incubated for 30 min with various amounts of non-radiolabeled M1 protein in PBS containing 10% plasma or 0.3 mg/ml fibrinogen. After centrifugation the pellets were resuspended in PBS and the precipitated M protein was detected by γ-counting.

Scanning electron microscopy - Probes were gently applied to Millipore filters (Waters Corporation, Milford). Samples were then sucked down to the filters by a wet filter paper lying underneath. The filters were fixed in 2% (v/v) glutaraldehyde, 0.1 M sodium cacodylate, 0.1 M sucrose, pH 7.2 for 1 h at 4°C, and washed with 0.15 M cacodylate, pH 7.2. The filters were postfixed with 1% (w/v) osmium tetroxide, 0.15 M sodium cacodylate, pH 7.2, for 1 h at 4°C, washed, and stored in cacodylate buffer. Fixed filter paper samples were dehydrated with an ascending ethanol series (10 min per step), dried, mounted on aluminum holders, sputtered with palladium/gold, and examined in a Jeol JSM-350 scanning electron microscope.

Thin-sectioning and transmission electron microscopy - Samples were fixed for 1h at room temperature and then overnight at 4°C in 2.5 % glutaraldehyde in 0.15 M sodium cacodylate, pH 7.4 (cacodylate buffer). Afterwards, they were washed with cacodylate buffer and postfixed for 1 h at room temperature in 1 % osmium tetroxide in cacodylate buffer and dehydrated in a graded series of ethanol and then embedded in Epon 812 using acetone as intermediate solvent. Specimens were sectioned with a diamond knife into 50 nm-thick ultrathin sections on an LKB ultramicrotome. The ultrathin sections were stained with uranyl acetate and lead citrate. Specimens were observed in a Jeol JEM 1230

electron microscope operated at 80 kV accelerating voltage. Images were recorded with a Gatan Multiscan 791 CCD camera.

Clotting assay - The thrombin clotting time (TCT) was measured in a coagulometer (Amelung, Lemgo, Germany). Samples of 200 µl human citrate-treated plasma were
5 incubated with 4 µl of peptide H-2395 or H-2940 (5 mg/ml) for 15 min at 37°C. Clotting was initiated by adding 100 µl of the TCT reagent (Sigma Chemicals, St. Louis, MO).

Preparation and stimulation of mouse bone marrow cells and leukocytes - For each sample preparation, bone marrow cells and whole blood were collected from 3 to 5 mice. Bone marrow cells were harvested from the femur bones of the mice, pooled and
10 suspended in calcium-free PBS. Whole blood was collected by cardiac puncture and anticoagulated with 10 mM EDTA (Gautam et al., 2001, Nat. Med., 7, 1123-1127). Blood leukocytes were isolated using Dextran sedimentation. Cells from blood and bone marrow were counted using a Bürker chamber. The WBC were washed twice in PBS and resuspended to 1×10^7 cells/ml. In order to stimulate release of granule proteins, WBC
15 (approximately 10^7 cells/ml) were pre-incubated with cytochalasin B (10 µM) at room temperature for 5 minutes, followed by incubation with 100 nM fMLP for another 30 min at 37°C. After centrifugation (2000 x g; 10 min) the supernatant was collected for further analysis. Alternatively, WBC were lysed by adding 1% boiling SDS in 10 mM Tris-HCl pH 7.4. The solution was boiled for an additional 5 min and then sonicated briefly and
20 analyzed by SDS-PAGE, followed by Western blotting and immunoprinting. For functional studies, cells were lysed by incubation in water for 10 minutes followed by a centrifugation step (10 min at 500 x g).

RNA preparation - RNA was prepared from bone marrow cells, harvested from murine femur bones. The cells were pelleted by centrifugation at 400 g. Total RNA was
25 then prepared using the Trizol reagent (Gibco Life Technologies) and the purity was assessed from the ratio $A_{260/280}$ (typically >1.8).

RT-PCR - RT-PCR was conducted with GeneAmp/PerkinElmer RNA PCR kit according to the manufacturer's protocol. Briefly, total RNA (500 ng) in water was heated (65°C, 10 min), chilled on ice, and reverse transcribed (20 min, 42°C) with 5' primer GG GTT GTT GAG
30 AA 3' derived from the genomic sequence (NM 001700) of human HBP), 1 U/µl RNase inhibitor, and 2.5 % de-ionized formamide. After denaturation (5 min, 99°C), samples

were amplified in PCR buffer (1.5 mM MgCl₂, 0.2 mM dNTPs, 1 μM primer, 2.5% de-ionized formamide, and 0.05 U/μl *Taq* polymerase) for 20-35 cycles with annealing between 50 and 60°C and extension at 72°C, using a PerkinElmer/GeneAmp PCR system 2400. Products were analyzed by agarose gel electrophoresis (1% gels).

5 *Animals* - Adult male mice (approximately 30 g) of the C57BL/6 strain were used. Animals were anaesthetized with equal parts of fluanison/fentanyl (Hypnorm 10, 0.2 mg/ml) and midazolam (Dormicum, 5 mg/ml) diluted 1:1 with sterile water (dose: 0.2 ml / mouse i.m.). The anaesthesia was supplemented with inhalation of 2% isoflurane. All animal experiments were approved by the regional ethical committee. Mice were given an
10 intravenous injection of 100 μl of a solution containing 150 μg/ml M1 protein. Alternatively, 100 μl of a solution containing 150 μg/ml M1 protein and 4 mg/ml Gly-Pro-Arg-Pro or Gly-His-Arg-Pro were intravenously injected. As control vehicle alone was applied via the same route. 30 min after injection, mice were sacrificed and the lungs were removed. Alternatively, 100 μl of a bacteria solution (2 x 10⁹ AP1 bacteria/ml in the
15 presence or absence of 400 μg Gly-Pro-Arg-Pro or Gly-His-Arg-Pro) were injected together with 0.9 ml of air into the dorsal region of the mouse. After 30 min, mice were given an intravenous injection of 100 μl of a solution containing PBS or 2 mg/ml Gly-Pro-Arg-Pro or Gly-His-Arg-Pro, respectively. Six hours after infection, mice were sacrificed and the lungs were removed.

20 *Histochemistry* – Mice were sacrificed, lungs rapidly removed by surgery and fixed at 4°C for 24 h in buffered 4% formalin (pH 7.4; Kebo). Tissues were dehydrated and imbedded in paraffin (Histolab Products AB), cut into 4-μm sections, and mounted. After removal of the paraffin, tissues were stained with Mayers hematoxylin (Histolab Products AB) and eosin (Surgipath Medical Industries, Inc.).

25 *Immunofluorescence and confocal microscopy* - Snap-frozen biopsies of tissue, collected either from the epi-center of infection (fascia) or from a distal site with no evidence of inflammation (muscle), from a patient with necrotizing fasciitis caused by an M1T1 *S. pyogenes* strain (kindly provided by Prof. Donald E Low, Mount Sinai Hospital, Toronto, Canada) were cryosectioned and fixed as previously described (Norrby-Teglund
30 et al., 2001). Tissue sections were initially blocked with 20% fetal calf serum in PBS-saponin (Sigma, St. Louis, MO) for 30 minutes followed by avidin and biotin blocking

(Vector laboratories, Burlingame, CA) 15 minutes each, and finally 30 minutes incubation with PBS-saponin containing 0.1% BSA-c (Aurion, Wageningen, The Netherlands). All antibodies and fluorochromes were diluted in PBS-saponin-BSA-c. Staining for the M1 protein was achieved by incubation with a polyclonal rabbit antiserum against M1 (diluted 1:10 000) overnight, followed by a 30 minutes incubation with biotinylated goat-anti-rabbit IgG (diluted 1:500, Vector Laboratories, Burlingame, CA), and subsequent addition of streptavidin conjugated Alexa Fluor 488 diluted 1:600 (Molecular Probes, Eugene, OR, USA). Double staining for fibrinogen was obtained through direct labelling of purified rabbit anti-fibrinogen antibodies diluted to a concentration of 3mg/ml (Dakocytomation) by Zenon Alexa fluor 532 IgG labelling kit (Molecular Probes) and incubation with the tissue sections for 90 minutes. Vectashield supplemented with dapi (Vector Lab.) was used as mounting media. A polyclonal rabbit antiserum against the Lancefield group A carbohydrate was used to detect *S. pyogenes* (Norrby-Teglund et al., 2001) and served as a positive control to verify the specificity of the M1-staining. Single stainings were also performed to assure specificity of staining patterns. For evaluation, the Leica confocal scanner TCS2 AOBS with an inverted Leica DMIRE2 microscope was used.

Results

Neutrophil proteinases release M1 protein from the surface of *S. pyogenes*

To test whether M1 protein is released from the streptococcal surface following treatment with human neutrophil proteinases, AP1 bacteria (2×10^9 bacteria/ml) were incubated with serial dilutions (100 μ l, 10 μ l or 1 μ l) of secretion products (exudates) from PMNs (2×10^6 cells/ml) stimulated by antibody-crosslinking of CD11b/CD18 for 2 hours at 37°C. Activation of the β_2 integrins by antibody-crosslinking mimics adhesion-dependent receptor engagement and induces the release of neutrophil elastase, cathepsin G, and proteinase 3 (Gautam et al., 2000, J. Exp. Med., **191**, 1829-1839), which we confirmed in our experimental settings in an indirect ELISA (data not shown). Incubation of the neutrophil exudates with AP1 bacteria resulted in the solubilization of several streptococcal proteins from the bacterial cell wall. This was seen by centrifugation of bacteria and separating the supernatants by SDS-PAGE (data not shown). The presence of M1 protein among the solubilized proteins was analyzed by Western blot analysis using a polyclonal antiserum against M1 protein. After SDS-PAGE, the solubilized proteins were

transferred onto nitrocellulose and probed with antibodies to M1 protein. Bound antibody was detected by a peroxidase-conjugated secondary antibody to rabbit immunoglobulin, followed by the chemiluminescence detection method. The supernatant from untreated bacteria was used as a control.

5 In the absence of released neutrophil components, only small amounts of M1 protein were found in bacterial supernatants, whereas larger quantities of M1 protein fragments with different molecular masses were detected when bacteria were incubated with increasing volumes of neutrophil secretion products. The size of the largest M1 protein fragment in comparison to purified M1 suggested that it covers most, if not all, of the
10 extra-cellular part of the M1 protein. With increasing concentrations of neutrophil secretion products M1 protein was further degraded.

To test whether the generated M1 protein fragments were still capable of binding fibrinogen, solubilized streptococcal proteins (10ng purified M1 protein, AP1 surface proteins released with 100µl neutrophilic secretion products and 10ng purified protein H)
15 were run on SDS-PAGE after treatment with the highest volume of neutrophil exudate. They were then transferred onto nitrocellulose and probed with fibrinogen (2µg/ml). Bound fibrinogen was then immuno-detected with specific antibodies against fibrinogen and a peroxidase-conjugated antibody against rabbit immunoglobulin, as described earlier. *E. coli*-produced soluble M1 protein binds fibrinogen with high affinity, whereas the
20 closely related protein H shows no interaction with fibrinogen (Åkesson et al., 1994, Biochem. J., 300, 877-886; Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). This was demonstrated in our results, which also showed that the treatment with secreted neutrophil components released two fibrinogen-binding fragments from AP1 bacteria. The molecular masses of these fragments correlated well with the M1 protein fragments seen
25 earlier. Transmission electron microscopy analyses of thin-sectioned AP1 bacteria before and after incubation with neutrophil exudates (100µl PMN exudate/10⁶ bacteria) revealed that these products efficiently removed the fibrous surface proteins of AP1 bacteria. These hair-like structures represent M protein and the results show that the neutrophil exudates release fibrinogen-binding M1 protein fragments from the bacterial surface.

30 **M1 protein triggers the release of heparin-binding protein (HBP) from PMNs in human blood**

The inflammatory mediator HBP is released by PMNs, the only blood cells that were reported to produce HBP (Edens and Parkos, 2003, Curr. Opin. Haematol. 10, 25-30), and *S. pyogenes* is known to be a potent inducer of inflammation. The observation that fragments of M1 protein were solubilized by neutrophil proteinases raised the question whether these fragments and/or other *S. pyogenes* components could enhance the inflammatory response by releasing HBP from PMNs. Soluble streptococcal components were therefore added to human whole blood. Figure 1A shows that about 63% of the HBP stored in PMNs was mobilized when M1 protein at a final concentration of 1 µg/ml was added to blood. Interestingly, both lower and higher concentrations resulted in less efficient HBP release. Apart from M1 protein, formyl-methionyl-leucyl-phenylalanine (fMLP) and lipoteichoic acid (LTA) evoked secretion of HBP. However, in contrast to the M1 protein-induced release, these effects were dose dependent. Hyaluronic acid (HA), which is part of the streptococcal capsule, and the secreted streptococcal proteins SpeB and protein SIC, did not induce HBP release. Protein H, an IgG-binding surface protein of AP1 bacteria (Åkesson et al., 1990, Mol. Immunol., 27, 523-531), is structurally closely related to the M1 protein, but does not bind fibrinogen (Åkesson et al., 1994, Biochem. J., 300, 877-886). Only minute amounts of HBP were secreted following the addition of protein H to blood.

To localize the region in the M1 protein that triggers secretion of HBP from PMNs, fragments A-S and S-C3 (Åkesson et al., 1994, Biochem. J., 300, 877-886) derived from the M1 protein (Fig. 1B, top), were tested. Figure 1B shows that treatment with fragment A-S led to mobilization of HBP, whereas fragment S-C3 had no effect. The results demonstrate that the NH₂-terminal part of the M1 protein is required for HBP release. Previous studies have identified fibrinogen-binding site(s) in the B domains of fragment A-S, albumin-binding sites in the C repeats of S-C3, and IgG-Fc-binding activity in the S region, which is present in both fragments (Åkesson et al., 1994, Biochem. J., 300, 877-886). The M1 protein and its two fragments are recombinant proteins produced in *E. coli*. However, also M1 protein produced by *S. pyogenes* releases HBP, as shown with an isogenic AP1 mutant strain, termed MC25, expressing a truncated M1 protein lacking the COOH-terminal cell wall anchoring motif. This strain has no surface-bound M1 protein, but produces an M1 protein fragment that is secreted into the growth medium (Collin and

Olsén, 2000, Mol. Microbiol., 36, 1306-1318). Figure 1C shows that supernatants of an overnight culture from MC25 bacteria triggered the release of HBP, while culture supernatants from AP1 bacteria or growth medium alone did not have this effect. The results demonstrate that soluble M1 protein produced by *E. coli* or *S. pyogenes* induces HBP release in human blood.

The release of HBP from PMNs in human blood is modulated by signal transduction mediators and extracellular divalent metal ions

PMNs release their granular content upon cell lysis or by a regulated secretory mechanism involving a sophisticated signal transduction machinery (Borregaard and Cowland, 1997, Blood, 89, 3503-3521). To investigate by which mechanism M1 protein induces mobilization of HBP in human blood, the influence of signal transduction inhibitors on HBP release was analyzed. Theoretically, fMLP contamination of the M1 protein preparation could cause activation of PMNs, and the first substances tested were t-boc-MLP (an fMLP antagonist) and pertussis toxin (an antagonist of G_i protein-coupled seven membrane spanning receptors, to which fMLP receptors belong). As shown in Figure 2 and Table 1, none of the two components inhibited the release of HBP, implicating that fMLP was not present in the M1 protein preparation and that M1 protein does not act as an fMLP receptor agonist. The next signal transduction inhibitors to be employed were genistein (a tyrosine kinase inhibitor (O'Dell et al., 1991, Nature, 353, 558-560)) and wortmannin (a phosphatidylinositol 3-kinase inhibitor (Cardenas et al., 1998, Trends Biotechnol., 16, 427-433)). These inhibitors abrogate down-stream effects of β_2 integrin-triggered PMN signaling (Axelsson et al., 2000, Exp. Cell. Res., 256, 257-263), and both blocked the release of HBP almost completely. To study the effect of intracellular and extracellular calcium, cells were incubated with BAPTA (complexing intracellular calcium) and EGTA (complexing extracellular calcium). Like genistein and wortmannin, this treatment inhibited the mobilization of HBP. When EGTA was used in the absence of BATPA, it also blocked HBP release. These results suggest that the binding of M1 protein to PMNs is dependent on divalent metal ions. Other inhibitors which are mainly involved in the signal transduction pathways of G protein-coupled receptors and growth hormone receptors, such as AG1478 (a selective inhibitor of EGF receptor tyrosine kinase (Osherov and Levitzki, 1994, Eur. J. Biochem., 225, 1047-

1053)), GF109203 (a protein kinase C inhibitor (Toullec et al., 1991, J. Biol. Chem., 266, 15771-15781)), H-89 (an inhibitor of cAMP-dependent protein kinase (PKA) (Fujihara et al., 1993, J. Biol. Chem., 268, 14898-14905)), PD98059 (an inhibitor of the MAPK pathway (Dudley et al., 1995, Proc. Natl. Acad. Sci. USA, 92, 7686-7689)), and U-73122
5 (a phospholipase C inhibitor (Smallridge et al., 1992, Endocrinology, 131, 1883-1888)), did not interfere with the secretion of HBP. Taken together, the results show that the release of HBP induced by M1 protein is dependent on the binding of the streptococcal protein to a receptor-like structure located at the neutrophil surface. The data also demonstrate that the binding is dependent on extracellular divalent metal ions.

10 M1 protein precipitates fibrinogen in plasma

To identify a neutrophil receptor mediating the release of HBP in blood, binding of ^{125}I -M1 protein to purified PMNs was tested. However, no significant binding to the PMNs was detected, suggesting that the interaction requires a co-factor, presumably a plasma protein. One of our initial observations was that the addition of M1 protein (at a
15 concentration of 1 $\mu\text{g/ml}$) to plasma (diluted 1/10) provoked a visible precipitation, while at other concentrations of M1 protein no precipitate was formed in the plasma sample (Fig. 3A). Notably, maximal release of HBP from PMNs was also recorded at a M1 protein concentration of 1 $\mu\text{g/ml}$ blood diluted 1/10 (Fig. 3B), suggesting that M1 precipitation and HBP release are correlated. The finding that M protein forms
20 precipitates in human plasma was reported already in 1965, and was found to be the result of interactions between M protein and fibrinogen (Kantor, 1965, J. Exp. Med., 121, 849-859). The interaction between purified M1 protein and fibrinogen in solution was therefore investigated, and also in this case a precipitate was formed at the same concentrations of M1 protein and fibrinogen as in plasma (Fig. 3C). In contrast, no
25 precipitation occurred when M1 protein was added to fibrinogen-deficient plasma (data not shown). The presence of serine proteinase inhibitors did not influence M1 protein-induced precipitation, indicating that a thrombin-like cleavage of fibrinogen did not cause the precipitation (data not shown). Scanning electron micrographs of the precipitates revealed amorphous aggregation, where individual protein components could not be
30 distinguished. In contrast, plasma clots induced by thrombin showed networks of fibrin fibrils similar to those described previously (Herwald et al., 1998, Nat. Med., 4, 298-302;

Persson et al., 2000, J. Exp. Med., 192, 1415-1424). Analysis by transmission electron microscopy of ultra-thin sections at higher resolution showed irregular micro-fibrillar M1 protein/plasma precipitates and highly organized cross-striated thrombin-induced fibrin fibrils. The results show that M1 protein, when added to human plasma in a narrow concentration range, has the potential to trigger plasma precipitation. The precipitate formed is morphologically different from a physiological clot induced by thrombin.

Precipitates of M1 protein and fibrinogen activate PMNs

In another set of experiments, we analyzed the interaction between M1 protein/fibrinogen precipitates and PMNs by scanning electron microscopy. The results showed that PMNs reconstituted with a mixture containing M1 protein (1 µg/ml) and human plasma (10% in PBS) formed aggregates that are covered with an amorphous proteinous layer, similar to the M1 protein/fibrinogen precipitates seen earlier. No precipitation or aggregation was found when PMNs were reconstituted with plasma in the absence of M1 protein, or when PMNs were treated with M1 protein dissolved in buffer instead of plasma. Purified PMNs incubated with buffer alone were used as a control. Additional experiments with plasma revealed that the aggregation of PMNs in the presence of M1 protein was fibrinogen-dependent (data not shown). The data indicate that the interaction between PMNs and M1 protein/fibrinogen complexes precipitates activates the cells, which results in HBP release. We therefore analyzed whether preformed M1 protein/fibrinogen precipitates are required for PMN activation. M1 protein (final concentration 1 µg/ml) was incubated with fibrinogen (0.3 mg/ml) or with plasma (diluted 1/10) for 30 min. Following centrifugation and washing, the resulting pellets were added to human blood (diluted 1/10) for 30 min and the release of HBP was determined. As a control, fibrinogen and plasma in the absence of M1 protein was treated in the same way. Figure 4 demonstrates that M1 protein-induced precipitates formed in a fibrinogen solution or in plasma caused HBP release, whereas the controls were negative. Combined the data described in this paragraph show that M1 protein/fibrinogen precipitates bind to PMNs and induce their aggregation and activation, which results in the release of HBP.

M1 protein-induced HBP release is blocked by a β_2 integrin antagonist

Human fibrinogen binds to PMNs via β_2 integrins (Altieri, 1999, Thromb. Haemost., 82, 781-786) and for CD11c/CD18 the binding site was mapped to the NH₂-terminal

region of the A α chain of fibrinogen. A peptide derived from this region (Gly-Pro-Arg-Pro), has been shown to block adherence of TNF-stimulated PMNs to fibrinogen-coated surfaces, while other peptides from the same region, including Gly-His-Arg-Pro, had no effect (Loike et al., 1991, Proc. Natl. Acad. Sci. USA, **88**, 1044-1048). Furthermore, it was demonstrated that antibodies against β_2 integrins inhibit the binding of fibrinogen to activated PMNs, and among these antibodies a monoclonal antibody (IB4) directed against the common β -chain of integrins, was the most potent (Loike et al., 1991, Proc. Natl. Acad. Sci. USA, **88**, 1044-1048). Platelet-induced activation of PMNs was also found to be dependent on the interaction between CD11c/CD18 and the A α chain of platelet-expressed fibrinogen (Ruf and Patscheke, 1995, Br. J. Haematol., **90**, 791-796). As shown for the binding of fibrinogen to PMNs, platelet-induced activation was also inhibited by the Gly-Pro-Arg-Pro peptide and by antibodies to CD11c, whereas the Gly-His-Arg-Pro peptide had no effect. These reports indicate that the binding of PMNs to immobilized fibrinogen (for instance on coverslips or platelets) involves the β_2 integrins leading to an activation of PMNs. Interestingly, Gly-Pro-Arg-Pro not only inhibits the binding of fibrinogen to β_2 integrins, but it also prevents clot formation (Laudano and Doolittle, 1980, Biochemistry, **19**, 1013-1019), and Figure 5A shows that Gly-Pro-Arg-Pro completely blocked thrombin-induced coagulation of normal plasma, while Gly-His-Arg-Pro did not influence the clotting time. It should be emphasized that Gly-Pro-Arg-Pro prevents fibrin-fiber formation by binding to the thrombin exposed polymerization sites of the fibrin molecules (Spraggon et al., 1997, Nature, **389**, 455-462). Thus, the effect of Gly-Pro-Arg-Pro on clot-formation is not integrin-dependent. The influence of the two peptides on the interaction between M1 protein and fibrinogen was tested in a competitive ELISA. However, none of the peptides had an effect in these assays (data not shown).

The Gly-Pro-Arg-Pro and Gly-His-Arg-Pro peptides, as well as antibodies to the β_2 integrins (IB4), were also tested for their ability to interfere with the M1 protein-induced secretion of HBP. As shown in Figure 5B, the addition of Gly-Pro-Arg-Pro to human blood blocked the mobilization of HBP by M1 protein in a dose dependent manner, and also antibody IB4 directed against the common β -chain of integrins impaired the release. The control substances, Gly-His-Arg-Pro and an unrelated antibody to H-kininogen, did not influence HBP secretion (Fig. 5B). The effect of Gly-Pro-Arg-Pro on M1 protein-

induced PMN aggregation was confirmed by scanning electron microscopy analysis. Gly-Pro-Arg-Pro inhibited the aggregation of purified PMNs in a mixture of plasma and M1 protein. In contrast, Gly-His-Arg-Pro had no effect on the aggregation of PMNs. These results support the notion that M1 protein-fibrinogen complexes activate PMNs through β_2 integrin ligation, which triggers the release of HBP. This mechanism appears to be similar to the previously described antibody-mediated cross-linking of CD11b/CD18 that mimics adhesion-dependent receptor engagement causing a massive release of HBP from PMNs (Gautam et al., 2000, J. Exp. Med., 191, 1829-1839).

Intravenous injection of M1 protein into mice causes severe lung lesions that are prevented by the administration of a β_2 integrin antagonist

So far, HBP has only been identified in humans and pigs (Flodgaard et al, 1991, Eur J. Biochem, 197, 535-547). Before mouse experiments were performed, we investigated whether an HBP homologue is also present in the mouse. To this end, bone marrow cells from mice were isolated and the existence of a murine HBP homologue was demonstrated by RT-PCR analysis and Western blot analysis. RT-PCR amplification of RNA prepared from bone marrow cells was carried out using a primer set derived from the human HBP sequence. Western blot detection was carried out after electrophoresis of human HPB and murine bone marrow lysate immunostained with antibodies against human HBP. A series of animal experiments was then conducted with anaesthetized mice. Three mice received M1 protein i.v. (15 μ g/animal); three were treated with a mixture of M1 protein (15 μ g/animal) and peptide Gly-Pro-Arg-Pro (400 μ g/animal); three with a mixture of M1 protein (15 μ g/animal) and peptide Gly-His-Arg-Pro (400 μ g/animal); and three with vehicle alone. Thirty minutes after administration the breathing of mice injected with M1 protein or M1 protein plus peptide Gly-His-Arg-Pro was clearly affected as compared to the other mice. The animals were sacrificed and the lungs were removed, stained with hematoxylin and eosin and subjected to light microscopy or analyzed by scanning electron microscopy. A representative lung sample from a mouse injected with buffer only showed intact lung tissue. Lung sections from mice injected with M1 protein, however, demonstrated severe hemorrhage and tissue destruction. These lesions were almost completely prevented when M1 protein was injected together with Gly-Pro-Arg-Pro, even though the tissue remained slightly swollen which is a sign of an ongoing inflammatory

reaction. By contrast, application of Gly-His-Arg-Pro could not prevent the M1 protein induced bleeding and tissue destruction. Protein H was injected as a control and analysis of the lung tissue revealed no hemorrhage and the alveoli appeared less swollen. In order to resolve lung lesions at higher magnification, tissue sections were analyzed by scanning electron microscopy. A lung section from a PBS-treated mouse showed no signs of any pulmonary damage. However, injection of the M1 protein resulted in severe leakage of erythrocytes as seen before, but also in the deposition of proteinous aggregates. The morphology of the aggregates resembled the M1 protein-induced amorphous plasma precipitates seen earlier. The lungs of mice injected with M1 protein and Gly-Pro-Arg-Pro contained no precipitates. However, some alveolar swelling and minor leakage of erythrocytes were observed indicating an inflammatory reaction. In contrast, treatment with Gly-His-Pro-Arg did not influence M1 protein-caused lung damage. The injection of protein H did neither cause serious bleeding nor did the tissue appear to be severely inflamed.

In order to quantify the degree of lung affection six randomly chosen lung tissue section from each of the twelve animals were analyzed by electron microscopy, and the ratio of lung area containing protein aggregates versus total lung area was determined. Less than 10% of the lung tissue of animal injected with buffer alone or with M1 protein plus the Gly-Pro-Arg-Pro peptide contained protein aggregates ($3 \pm 1\%$ and $6 \pm 2\%$, respectively). In contrast, 90% of the lungs of animals treated with M1 protein or a mixture of M1 protein and the Gly-His-Arg-Pro peptide contained protein aggregates ($90 \pm 2\%$ in both cases). These animal experiments suggest that M1 protein-fibrinogen aggregates activate PMNs via the β_2 integrins, resulting in massive vascular leakage and deposition of protein aggregates in the lung tissue. The results also show that this pathophysiological effect can be blocked when fibrinogen-induced crosslinking of β_2 integrins is prevented by the Gly-Pro-Arg-Pro peptide.

Gly-Pro-Arg-Pro prevents vascular leakage and lung damage in mice infected with M1 protein expressing *S. pyogenes* bacteria

In a second series of animal experiments, nine mice were subcutaneously infected with M1 protein expressing *S. pyogenes* bacteria. Three mice in each group were treated with peptides Gly-Pro-Arg-Pro and Gly-His-Arg-Pro as described in Material and

Methods, respectively, while three mice received no treatment. As a control, three mice were given a subcutaneous injection of PBS. Six hours after infection, animals were sacrificed, lungs removed and examined by scanning electron microscopy. Analysis of blood samples from the animals revealed no occurrence of streptococci, indicating that bacteria had not started to disseminate from the site of infection. Electron micrographs of representative lung tissue sections from these animals were obtained. Recovered lungs from mice that received buffer instead of bacteria showed no signs of pulmonary damage. However, mice that were infected with streptococci were suffering from severe lung lesions indicated by massive infiltration of erythrocytes and fibrin deposition. When infected animals were treated with Gly-Pro-Arg-Pro, the lungs appeared to be much less affected, whereas treatment with Gly-His-Arg-Pro failed to prevent pulmonary damage. Lungs from mice infected with streptococci were further analyzed by immuno-staining electron microscopy by using antibodies against M1 protein. This showed that the M1 protein was found in the infiltrated precipitates. In contrast, no M1 protein staining was observed when lungs from non-infected animals were examined. Taken together, these results suggest that in an infectious model, shedded M1 protein is found in the circulation prior to dissemination of bacteria forming precipitates that deposits in the lungs of infected animals.

M1 protein/fibrinogen precipitates are formed in a patient with streptococcal toxic shock syndrome and necrotizing fasciitis

STSS constitutes a serious complication from a streptococcal infection and is associated with high morbidity and mortality (for a review see (Stevens, 2003, Curr Infect Dis Rep, 5, 379-386). Clinical signs of STSS are acute pain, erythema of the extremity, hypotension, fever, soft-tissue swelling, and respiratory failure (Stevens, 2000, Annu Rev Med, 51, 271-288). As our *in vitro* and *in vivo* data imply that some of these symptoms could be caused by the interaction between M1 protein and fibrinogen and the subsequent release of HBP, we analyzed tissue sections from a patient suffering from STSS necrotizing fasciitis caused by infection with an M1 protein-expressing M1T1 strain. A tissue section was sectioned, fixed, stained for M1 protein and fibrinogen and examined by confocal immuno-fluorescence microscopy by using antibodies against human fibrinogen and M1 protein (as described in Materials and Methods). The micrograph

revealed large amounts of streptococci found at the epi-center of infection (i.e. fascia) with the M1 protein which was readily detected in these areas. Although some of the M1 protein was found associated with the bacteria, the vast majority of the protein was released from the streptococcal surface. Non-specific staining was ruled out since the M1 protein was not detected in biopsies from distal areas with no or only very low bacterial load. Importantly, the shedded M1 protein was strongly co-localized with fibrinogen at the local site of infection, demonstrating that the amount of released M1 protein that was generated during the course of infection was sufficient to form precipitates with fibrinogen. Taken together the results provide strong evidence that in patients suffering from STSS necrotizing fasciitis, the release of M1 protein from the bacterial surface followed by the formation of M1 protein/fibrinogen precipitates presents an important virulence mechanism.

Table 1: Inhibition of M1 protein-induced release of HBP in human blood

substance	target	effect
t-boc-MLP	fMLP receptor	no inhibition
pertussis toxin	G _i protein-coupled seven membrane spanning receptors	no inhibition
genistein	tyrosine kinases	full inhibition
wortmannin	phosphatidylinositol 3-kinase	full inhibition
BAPTA and EGTA	intra- and extracellular calcium	full inhibition
EGTA	extracellular calcium	full inhibition
AG1478	EGF receptor tyrosine kinase	no inhibition
GF109203	protein kinase C	no inhibition
H-89	cAMP-dependent protein kinase	no inhibition
PD98059	MAPK pathway	no inhibition
U-73122	phospholipase C	no inhibition

CLAIMS

1. A method for identifying an anti-streptococcal agent, which method comprises:

5 (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof;

(b) providing, as a second component, isolated fibrinogen or a functional variant thereof;

10 (c) providing, as a third component, an isolated β_2 integrin or a functional variant thereof;

(d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and

(e) determining whether the test substance inhibits the interaction between the components;

15 thereby to determine whether a test substance is an anti-streptococcal agent.

2. A method for identifying an anti-streptococcal agent, which method comprises:

(a) providing, as a first component, a streptococcal M protein or a functional variant thereof;

20 (b) providing, as a second component, fibrinogen or a functional variant thereof;

(c) providing, as a third component, one or more polymorphonuclear neutrophils (PMNs);

25 (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and

(e) monitoring any inhibition of the activation of PMNs;
thereby to determine whether a test substance is an anti-streptococcal agent.

3. A method according to claim 2 wherein step (d) comprises contacting *S. pyogenes*, fibrinogen and PMNs in the presence of a test substance.

30 4. A method according to claim 2 or 3 wherein inhibition of the activation of PMNs is monitored by measuring the release of heparin binding protein (HBP).

5. A method according to any one of the preceding claims wherein the first component is provided by contacting *Streptococcus pyogenes* with a protease.

6. A method according to claim 5 wherein the protease is derived from a PMN.

7. A method according to claim 5 wherein the protease is endogenous to *S. pyogenes*.

8. A method according to any one of the preceding claims wherein the streptococcal M protein is the M1 protein of *S. pyogenes*, a homologue thereof which maintains the ability to form a complex with fibrinogen, or a functional variant of either thereof which maintains the ability to form a complex with fibrinogen.

9. A method according to claim 8, wherein the functional variant is a fragment of the M1 protein of *S. pyogenes* or a fragment of a homologue thereof.

10. A method according to claim 1, wherein step (e) comprises determining whether the components form aggregates in the presence of the test substance.

11. A test kit suitable for use in identifying a test substance which is capable of inhibiting the interaction between a streptococcal M protein or a functional variant thereof, fibrinogen and a functional variant thereof and a β_2 integrin or a functional variant thereof, which kit comprises:

- 20 (a) an isolated streptococcal M protein or a functional variant thereof;
(b) isolated fibrinogen or a functional variant thereof; and
(c) an isolated β_2 integrin or a functional variant thereof.

12. A test kit suitable for use in identifying a test substance which is capable of inhibiting the interaction between a streptococcal M protein or a functional variant thereof, fibrinogen or a functional variant thereof and PMNs, which kit comprises:

- 25 (a) a streptococcal M protein or a functional variant thereof;
(b) fibrinogen or a functional variant thereof; and
(c) one or more PMNs.

30 13. A test kit according to claim 11 or 12 which further comprises one or more buffers.

14. A test kit according to any one of claims 11 to 13 further comprising means for determining whether a test substance disrupts the interaction between the components.
15. An anti-streptococcal agent identified by a method according to any one of claims 1 to 10.
16. An anti-streptococcal agent according to claim 15 for use in a method of treatment of the human or animal body by therapy.
17. Use of an integrin antagonist in the manufacture of a medicament for the treatment of a streptococcal infection.
18. Use according to claim 17 wherein the antagonist is an anti-integrin antibody, a peptide mimetic or a non-peptide mimetic.
19. Use of an inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin in the manufacture of a medicament for the treatment of a streptococcal infection.
20. Use according to claim 19 wherein the inhibitor is a peptide comprising the sequence GPRP.
21. Use according to claim 19 wherein the inhibitor is an antibody which specifically binds the B-repeats of *S. pyogenes* M1 protein.
22. Use of an agent identified by a method according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment of a streptococcal infection.
23. A method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an agent identified by a method according to any one of claims 1 to 10 to a said individual.
24. A method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an integrin antagonist to a said individual.
25. A method of treating an individual suffering from a streptococcal infection comprising administering a therapeutically effective amount of an inhibitor of the interaction between streptococcal M protein, fibrinogen and β_2 integrin to a said individual.
26. A pharmaceutical composition comprising an inhibitor of the interaction

between streptococcal M protein, fibrinogen and β_2 integrin identified by a method of any one of claims 1 to 10 and a pharmaceutically acceptable carrier or diluent.

27. A method for providing a pharmaceutical composition, which method comprises:

5 (a) identifying an agent that inhibits the interaction between streptococcal M protein, fibrinogen and β_2 integrin by a method according to any one of claims 1 to 10; and

(b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent.

10 28. A method of treating an individual suffering from a streptococcal infection, which method comprises:

(a) identifying an agent that inhibits the interaction between streptococcal M protein, fibrinogen and β_2 integrin by a method according to any one of claims 1 to 10; and

15 (b) administering a therapeutically effective amount of the inhibitor thus identified to a said individual.

SEQUENCE LISTING

JC20 Rec'd PCT/PTO 21 OCT 2005

<110> HANSA MEDICAL RESEARCH AB

<120> METHOD AND TREATMENT

<130> N.87400B SER/SJB

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 484

<212> PRT

<213> Streptococcus pyogenes

<400> 1

```

Met Ala Lys Asn Asn Thr Asn Arg His Tyr Ser Leu Arg Lys Leu Lys
1          5          10          15
Thr Gly Thr Ala Ser Val Ala Val Ala Leu Thr Val Leu Gly Ala Gly
20          25          30
Phe Ala Asn Gln Thr Glu Val Lys Ala Asn Gly Asp Gly Asn Pro Arg
35          40          45
Glu Val Ile Glu Asp Leu Ala Ala Asn Asn Pro Ala Ile Gln Asn Ile
50          55          60
Arg Leu Arg Tyr Glu Asn Lys Asp Leu Lys Ala Arg Leu Glu Asn Ala
65          70          75          80
Met Glu Val Ala Gly Arg Asp Phe Lys Arg Ala Glu Glu Leu Glu Lys
85          90          95
Ala Lys Gln Ala Leu Glu Asp Gln Arg Lys Asp Leu Glu Thr Lys Leu
100         105         110
Lys Glu Leu Gln Gln Asp Tyr Asp Leu Ala Lys Glu Ser Thr Ser Trp
115         120         125
Asp Arg Gln Arg Leu Glu Lys Glu Leu Glu Glu Lys Lys Glu Ala Leu
130         135         140
Glu Leu Ala Ile Asp Gln Ala Ser Arg Asp Tyr His Arg Ala Thr Ala
145         150         155         160
Leu Glu Lys Glu Leu Glu Glu Lys Lys Lys Ala Leu Glu Leu Ala Ile
165         170         175
Asp Gln Ala Ser Gln Asp Tyr Asn Arg Ala Asn Val Leu Glu Lys Glu
180         185         190
Leu Glu Thr Ile Thr Arg Glu Gln Glu Ile Asn Arg Asn Leu Leu Gly
195         200         205
Asn Ala Lys Leu Glu Leu Asp Gln Leu Ser Ser Glu Lys Glu Gln Leu
210         215         220
Thr Ile Glu Lys Ala Lys Leu Glu Glu Glu Lys Gln Ile Ser Asp Ala
225         230         235         240
Ser Arg Gln Ser Leu Arg Arg Asp Leu Asp Ala Ser Arg Glu Ala Lys
245         250         255
Lys Gln Val Glu Lys Asp Leu Ala Asn Leu Thr Ala Glu Leu Asp Lys
260         265         270
Val Lys Glu Asp Lys Gln Ile Ser Asp Ala Ser Arg Gln Gly Leu Arg
275         280         285
Arg Asp Leu Asp Ala Ser Arg Glu Ala Lys Lys Gln Val Glu Lys Asp
290         295         300
Leu Ala Asn Leu Thr Ala Glu Leu Asp Lys Val Lys Glu Glu Lys Gln
305         310         315         320
Ile Ser Asp Ala Ser Arg Gln Gly Leu Arg Arg Asp Leu Asp Ala Ser
325         330         335
Arg Glu Ala Lys Lys Gln Val Glu Lys Ala Leu Glu Glu Ala Asn Ser

```

2/14

	340		345		350
Lys	Leu	Ala	Leu	Glu	Lys
	355		360		365
Lys	Leu	Thr	Glu	Lys	Glu
	370		375		380
Glu	Ala	Lys	Ala	Leu	Lys
385			390		395
Ala	Lys	Leu	Arg	Ala	Gly
	405		410		415
Lys	Pro	Gly	Asn	Lys	Ala
	420		425		430
Gly	Thr	Lys	Pro	Asn	Gln
	435		440		445
Gln	Leu	Pro	Ser	Thr	Gly
	450		455		460
Ala	Leu	Thr	Val	Met	Ala
465			470		475
Lys	Glu	Glu	Asn		480

<210> 2
 <211> 4
 <212> PRT
 <213> artificial sequence

<220>
 <223> Protein

<400> 2
 Gly Pro Arg Pro
 1

<210> 3
 <211> 4
 <212> PRT
 <213> artificial sequence

<220>
 <223> Protein

<400> 3
 Gly His Arg Pro
 1

<210> 4
 <211> 13
 <212> DNA
 <213> artificial sequence

<220>
 <223> PCR primer

<400> 4
 ggggttggtga gaa
 13

<210> 5
 <211> 644
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1) .. (19)
 <223>

<220>
 <221> PROPEP
 <222> (20) .. (644)
 <223>

<220>
 <221> PEPTIDE
 <222> (20) .. (35)
 <223>

<220>
 <221> DOMAIN
 <222> (36) .. (644)
 <223> mature peptide

<400> 5
 Met Phe Ser Met Arg Ile Val Cys Leu Val Leu Ser Val Val Gly Thr
 -35 -30 -25 -20
 Ala Trp Thr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly
 -15 -10 -5
 Gly Val Arg Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys
 -1 1 5 10
 Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys Cys
 15 20 25
 Pro Ser Gly Cys Arg Met Lys Gly Leu Ile Asp Glu Val Asn Gln Asp
 30 35 40 45
 Phe Thr Asn Arg Ile Asn Lys Leu Lys Asn Ser Leu Phe Glu Tyr Gln
 50 55 60
 Lys Asn Asn Lys Asp Ser His Ser Leu Thr Thr Asn Ile Met Glu Ile
 65 70 75
 Leu Arg Gly Asp Phe Ser Ser Ala Asn Asn Arg Asp Asn Thr Tyr Asn
 80 85 90
 Arg Val Ser Glu Asp Leu Arg Ser Arg Ile Glu Val Leu Lys Arg Lys
 95 100 105
 Val Ile Glu Lys Val Gln His Ile Gln Leu Leu Gln Lys Asn Val Arg
 110 115 120 125
 Ala Gln Leu Val Asp Met Lys Arg Leu Glu Val Asp Ile Asp Ile Lys
 130 135 140
 Ile Arg Ser Cys Arg Gly Ser Cys Ser Arg Ala Leu Ala Arg Glu Val
 145 150 155
 Asp Leu Lys Asp Tyr Glu Asp Gln Gln Lys Gln Leu Glu Gln Val Ile
 160 165 170
 Ala Lys Asp Leu Leu Pro Ser Arg Asp Arg Gln His Leu Pro Leu Ile
 175 180 185
 Lys Met Lys Pro Val Pro Asp Leu Val Pro Gly Asn Phe Lys Ser Gln
 190 195 200 205
 Leu Gln Lys Val Pro Pro Glu Trp Lys Ala Leu Thr Asp Met Pro Gln
 210 215 220
 Met Arg Met Glu Leu Glu Arg Pro Gly Gly Asn Glu Ile Thr Arg Gly
 225 230 235
 Gly Ser Thr Ser Tyr Gly Thr Gly Ser Glu Thr Glu Ser Pro Arg Asn
 240 245 250
 Pro Ser Ser Ala Gly Ser Trp Asn Ser Gly Ser Ser Gly Pro Gly Ser
 255 260 265
 Thr Gly Asn Arg Asn Pro Gly Ser Ser Gly Thr Gly Gly Thr Ala Thr
 270 275 280 285


```

Trp Lys Pro Gly Ser Ser Gly Pro Gly Ser Thr Gly Ser Trp Asn Ser
      290      295      300
Gly Ser Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro Gly Ser Pro
      305      310      315
Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly Ser Ser Glu Arg Gly
      320      325      330
Ser Ala Gly His Trp Thr Ser Glu Ser Ser Val Ser Gly Ser Thr Gly
      335      340      345
Gln Trp His Ser Glu Ser Gly Ser Phe Arg Pro Asp Ser Pro Gly Ser
      350      355      360      365
Gly Asn Ala Arg Pro Asn Asn Pro Asp Trp Gly Thr Phe Glu Glu Val
      370      375      380
Ser Gly Asn Val Ser Pro Gly Thr Arg Arg Glu Tyr His Thr Glu Lys
      385      390      395
Leu Val Thr Ser Lys Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys
      400      405      410
Val Thr Ser Gly Ser Thr Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr
      415      420      425
Val Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys
      430      435      440      445
Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met Asp
      450      455      460
Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe Arg His Arg
      465      470      475
His Pro Asp Glu Ala Ala Phe Phe Asp Thr Ala Ser Thr Gly Lys Thr
      480      485      490
Phe Pro Gly Phe Phe Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr
      495      500      505
Glu Ser Arg Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser
      510      515      520      525
Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser
      530      535      540
Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly
      545      550      555
Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala Asp Glu Ala Gly
      560      565      570
Ser Glu Ala Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala
      575      580      585
Lys Ser Arg Pro Val Arg Gly Ile His Thr Ser Pro Leu Gly Lys Pro
      590      595      600      605
Ser Leu Ser Pro

```

```

<210> 6
<211> 491
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> SIGNAL
<222> (1) .. (30)
<223>

```

```

<220>
<221> PEPTIDE
<222> (31) .. (44)
<223>

```

```

<220>
<221> DOMAIN
<222> (45) .. (491)
<223> mature peptide

```

<400> 6
 Met Lys Arg Met Val Ser Trp Ser Phe His Lys Leu Lys Thr Met Lys
 -40 -35 -30
 His Leu Leu Leu Leu Leu Leu Cys Val Phe Leu Val Lys Ser Gln Gly
 -25 -20 -15
 Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Gly His Arg Pro
 -10 -5 -1 1
 Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro
 5 10 15 20
 Pro Ile Ser Gly Gly Gly Tyr Arg Ala Arg Pro Ala Lys Ala Ala Ala
 25 30 35
 Thr Gln Lys Lys Val Glu Arg Lys Ala Pro Asp Ala Gly Gly Cys Leu
 40 45 50
 His Ala Asp Pro Asp Leu Gly Val Leu Cys Pro Thr Gly Cys Gln Leu
 55 60 65
 Gln Glu Ala Leu Leu Gln Gln Glu Arg Pro Ile Arg Asn Ser Val Asp
 70 75 80
 Glu Leu Asn Asn Asn Val Glu Ala Val Ser Gln Thr Ser Ser Ser Ser
 85 90 95 100
 Phe Gln Tyr Met Tyr Leu Leu Lys Asp Leu Trp Gln Lys Arg Gln Lys
 105 110 115
 Gln Val Lys Asp Asn Glu Asn Val Val Asn Glu Tyr Ser Ser Glu Leu
 120 125 130
 Glu Lys His Gln Leu Tyr Ile Asp Glu Thr Val Asn Ser Asn Ile Pro
 135 140 145
 Thr Asn Leu Arg Val Leu Arg Ser Ile Leu Glu Asn Leu Arg Ser Lys
 150 155 160
 Ile Gln Lys Leu Glu Ser Asp Val Ser Ala Gln Met Glu Tyr Cys Arg
 165 170 175 180
 Thr Pro Cys Thr Val Ser Cys Asn Ile Pro Val Val Ser Gly Lys Glu
 185 190 195
 Cys Glu Glu Ile Ile Arg Lys Gly Gly Glu Thr Ser Glu Met Tyr Leu
 200 205 210
 Ile Gln Pro Asp Ser Ser Val Lys Pro Tyr Arg Val Tyr Cys Asp Met
 215 220 225
 Asn Thr Glu Asn Gly Gly Trp Thr Val Ile Gln Asn Arg Gln Asp Gly
 230 235 240
 Ser Val Asp Phe Gly Arg Lys Trp Asp Pro Tyr Lys Gln Gly Phe Gly
 245 250 255 260
 Asn Val Ala Thr Asn Thr Asp Gly Lys Asn Tyr Cys Gly Leu Pro Gly
 265 270 275
 Glu Tyr Trp Leu Gly Asn Asp Lys Ile Ser Gln Leu Thr Arg Met Gly
 280 285 290
 Pro Thr Glu Leu Leu Ile Glu Met Glu Asp Trp Lys Gly Asp Lys Val
 295 300 305
 Lys Ala His Tyr Gly Gly Phe Thr Val Gln Asn Glu Ala Asn Lys Tyr
 310 315 320
 Gln Ile Ser Val Asn Lys Tyr Arg Gly Thr Ala Gly Asn Ala Leu Met
 325 330 335 340
 Asp Gly Ala Ser Gln Leu Met Gly Glu Asn Arg Thr Met Thr Ile His
 345 350 355
 Asn Gly Met Phe Phe Ser Thr Tyr Asp Arg Asp Asn Asp Gly Trp Leu
 360 365 370
 Thr Ser Asp Pro Arg Lys Gln Cys Ser Lys Glu Asp Gly Gly Gly Trp
 375 380 385
 Trp Tyr Asn Arg Cys His Ala Asn Pro Asn Gly Arg Tyr Tyr Trp
 390 395 400
 Gly Gly Gln Tyr Thr Trp Asp Met Ala Lys His Gly Thr Asp Asp Gly
 405 410 415 420
 Val Val Trp Met Asn Trp Lys Gly Ser Trp Tyr Ser Met Arg Lys Met

6/14

425
 Ser Met Lys Ile Arg Pro Phe Phe Pro Gln Gln
 440 445

435

<210> 7
 <211> 453
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1) .. (26)
 <223>

<220>
 <221> DOMAIN
 <222> (27) .. (453)
 <223> mature peptide

<400> 7
 Met Ser Trp Ser Leu His Pro Arg Asn Leu Ile Leu Tyr Phe Tyr Ala
 -25 -20 -15
 Leu Leu Phe Leu Ser Ser Thr Cys Val Ala Tyr Val Ala Thr Arg Asp
 -10 -5 -1 1 5
 Asn Cys Cys Ile Leu Asp Glu Arg Phe Gly Ser Tyr Cys Pro Thr Thr
 10 15 20
 Cys Gly Ile Ala Asp Phe Leu Ser Thr Tyr Gln Thr Lys Val Asp Lys
 25 30 35
 Asp Leu Gln Ser Leu Glu Asp Ile Leu His Gln Val Glu Asn Lys Thr
 40 45 50
 Ser Glu Val Lys Gln Leu Ile Lys Ala Ile Gln Leu Thr Tyr Asn Pro
 55 60 65 70
 Asp Glu Ser Ser Lys Pro Asn Met Ile Asp Ala Ala Thr Leu Lys Ser
 75 80 85
 Arg Ile Met Leu Glu Glu Ile Met Lys Tyr Glu Ala Ser Ile Leu Thr
 90 95 100
 His Asp Ser Ser Ile Arg Tyr Leu Gln Glu Ile Tyr Asn Ser Asn Asn
 105 110 115
 Gln Lys Ile Val Asn Leu Lys Glu Lys Val Ala Gln Leu Glu Ala Gln
 120 125 130
 Cys Gln Glu Pro Cys Lys Asp Thr Val Gln Ile His Asp Ile Thr Gly
 135 140 145 150
 Lys Asp Cys Gln Asp Ile Ala Asn Lys Gly Ala Lys Gln Ser Gly Leu
 155 160 165
 Tyr Phe Ile Lys Pro Leu Lys Ala Asn Gln Gln Phe Leu Val Tyr Cys
 170 175 180
 Glu Ile Asp Gly Ser Gly Asn Gly Trp Thr Val Phe Gln Lys Arg Leu
 185 190 195
 Asp Gly Ser Val Asp Phe Lys Lys Asn Trp Ile Gln Tyr Lys Glu Gly
 200 205 210
 Phe Gly His Leu Ser Pro Thr Gly Thr Thr Glu Phe Trp Leu Gly Asn
 215 220 225 230
 Glu Lys Ile His Leu Ile Ser Thr Gln Ser Ala Ile Pro Tyr Ala Leu
 235 240 245
 Arg Val Glu Leu Glu Asp Trp Asn Gly Arg Thr Ser Thr Ala Asp Tyr
 250 255 260
 Ala Met Phe Lys Val Gly Pro Glu Ala Asp Lys Tyr Arg Leu Thr Tyr
 265 270 275
 Ala Tyr Phe Ala Gly Gly Asp Ala Gly Asp Ala Phe Asp Gly Phe Asp
 280 285 290
 Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe Thr Ser His Asn Gly Met

7/14

```

295          300          305          310
Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp Lys Phe Glu Gly Asn Cys
          315          320          325
Ala Glu Gln Asp Gly Ser Gly Trp Trp Met Asn Lys Cys His Ala Gly
          330          335          340
His Leu Asn Gly Val Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala Ser
          345          350          355
Thr Pro Asn Gly Tyr Asp Asn Gly Ile Ile Trp Ala Thr Trp Lys Thr
          360          365          370
Arg Trp Tyr Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro Phe Asn
          375          380          385
Arg Leu Thr Ile Gly Glu Gly Gln Gln His His Leu Gly Gly Ala Lys
          395          400          405
Gln Val Arg Pro Glu His Pro Ala Glu Thr Glu Tyr Asp Ser Leu Tyr
          410          415          420
Pro Glu Asp Asp Leu
          425

```

```

<210> 8
<211> 1152
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> SIGNAL
<222> (1)..(16)
<223>

```

```

<220>
<221> DOMAIN
<222> (17)..(1152)
<223> mature peptide

```

```

<220>
<221> DOMAIN
<222> (150)..(328)
<223> Von Willebrand factor type A domain

```

```

<220>
<221> DOMAIN
<222> (164)..(350)
<223> I-domain (insertion domain)

```

```

<400> 8
Met Ala Leu Arg Val Leu Leu Leu Thr Ala Leu Thr Leu Cys His Gly
-15          -10          -5          -1
Phe Asn Leu Asp Thr Glu Asn Ala Met Thr Phe Gln Glu Asn Ala Arg
1          5          10          15
Gly Phe Gly Gln Ser Val Val Gln Leu Gln Gly Ser Arg Val Val
          20          25          30
Gly Ala Pro Gln Glu Ile Val Ala Ala Asn Gln Arg Gly Ser Leu Tyr
          35          40          45
Gln Cys Asp Tyr Ser Thr Gly Ser Cys Glu Pro Ile Arg Leu Gln Val
          50          55          60
Pro Val Glu Ala Val Asn Met Ser Leu Gly Leu Ser Leu Ala Ala Thr
          65          70          75          80
Thr Ser Pro Pro Gln Leu Leu Ala Cys Gly Pro Thr Val His Gln Thr
          85          90          95
Cys Ser Glu Asn Thr Tyr Val Lys Gly Leu Cys Phe Leu Phe Gly Ser
          100          105          110
Asn Leu Arg Gln Gln Pro Gln Lys Phe Pro Glu Ala Leu Arg Gly Cys

```

[illegible]

9/14

Glu	Phe	Asn	Pro	Arg	Glu	Val	Ala	Arg	Asn	Val	Phe	Glu	Cys	Asn	Asp	610	615	620
Gln	Val	Val	Lys	Gly	Lys	Glu	Ala	Gly	Glu	Val	Arg	Val	Cys	Leu	His	625	630	635
Val	Gln	Lys	Ser	Thr	Arg	Asp	Arg	Leu	Arg	Glu	Gly	Gln	Ile	Gln	Ser	645	650	655
Val	Val	Thr	Tyr	Asp	Leu	Ala	Leu	Asp	Ser	Gly	Arg	Pro	His	Ser	Arg	660	665	670
Ala	Val	Phe	Asn	Glu	Thr	Lys	Asn	Ser	Thr	Arg	Arg	Gln	Thr	Gln	Val	675	680	685
Leu	Gly	Leu	Thr	Gln	Thr	Cys	Glu	Thr	Leu	Lys	Leu	Gln	Leu	Pro	Asn	690	695	700
Cys	Ile	Glu	Asp	Pro	Val	Ser	Pro	Ile	Val	Leu	Arg	Leu	Asn	Phe	Ser	705	710	715
Leu	Val	Gly	Thr	Pro	Leu	Ser	Ala	Phe	Gly	Asn	Leu	Arg	Pro	Val	Leu	725	730	735
Ala	Glu	Asp	Ala	Gln	Arg	Leu	Phe	Thr	Ala	Leu	Phe	Pro	Phe	Glu	Lys	740	745	750
Asn	Cys	Gly	Asn	Asp	Asn	Ile	Cys	Gln	Asp	Asp	Leu	Ser	Ile	Thr	Phe	755	760	765
Ser	Phe	Met	Ser	Leu	Asp	Cys	Leu	Val	Val	Gly	Gly	Pro	Arg	Glu	Phe	770	775	780
Asn	Val	Thr	Val	Thr	Val	Arg	Asn	Asp	Gly	Glu	Asp	Ser	Tyr	Arg	Thr	785	790	795
Gln	Val	Thr	Phe	Phe	Phe	Pro	Leu	Asp	Leu	Ser	Tyr	Arg	Lys	Val	Ser	805	810	815
Thr	Leu	Gln	Asn	Gln	Arg	Ser	Gln	Arg	Ser	Trp	Arg	Leu	Ala	Cys	Glu	820	825	830
Ser	Ala	Ser	Ser	Thr	Glu	Val	Ser	Gly	Ala	Leu	Lys	Ser	Thr	Ser	Cys	835	840	845
Ser	Ile	Asn	His	Pro	Ile	Phe	Pro	Glu	Asn	Ser	Glu	Val	Thr	Phe	Asn	850	855	860
Ile	Thr	Phe	Asp	Val	Asp	Ser	Lys	Ala	Ser	Leu	Gly	Asn	Lys	Leu	Leu	865	870	875
Leu	Lys	Ala	Asn	Val	Thr	Ser	Glu	Asn	Asn	Met	Pro	Arg	Thr	Asn	Lys	885	890	895
Thr	Glu	Phe	Gln	Leu	Glu	Leu	Pro	Val	Lys	Tyr	Ala	Val	Tyr	Met	Val	900	905	910
Val	Thr	Ser	His	Gly	Val	Ser	Thr	Lys	Tyr	Leu	Asn	Phe	Thr	Ala	Ser	915	920	925
Glu	Asn	Thr	Ser	Arg	Val	Met	Gln	His	Gln	Tyr	Gln	Val	Ser	Asn	Leu	930	935	940
Gly	Gln	Arg	Ser	Pro	Pro	Ile	Ser	Leu	Val	Phe	Leu	Val	Pro	Val	Arg	945	950	955
Leu	Asn	Gln	Thr	Val	Ile	Trp	Asp	Arg	Pro	Gln	Val	Thr	Phe	Ser	Glu	965	970	975
Asn	Leu	Ser	Ser	Thr	Cys	His	Thr	Lys	Glu	Arg	Leu	Pro	Ser	His	Ser	980	985	990
Asp	Phe	Leu	Ala	Glu	Leu	Arg	Lys	Ala	Pro	Val	Val	Asn	Cys	Ser	Ile	995	1000	1005
Ala	Val	Cys	Gln	Arg	Ile	Gln	Cys	Asp	Ile	Pro	Phe	Phe	Gly	Ile		1010	1015	1020
Gln	Glu	Glu	Phe	Asn	Ala	Thr	Leu	Lys	Gly	Asn	Leu	Ser	Phe	Asp		1025	1030	1035
Trp	Tyr	Ile	Lys	Thr	Ser	His	Asn	His	Leu	Leu	Ile	Val	Ser	Thr		1040	1045	1050
Ala	Glu	Ile	Leu	Phe	Asn	Asp	Ser	Val	Phe	Thr	Leu	Leu	Pro	Gly		1055	1060	1065
Gln	Gly	Ala	Phe	Val	Arg	Ser	Gln	Thr	Glu	Thr	Lys	Val	Glu	Pro		1070	1075	1080
Phe	Glu	Val	Pro	Asn	Pro	Leu	Pro	Leu	Ile	Val	Gly	Ser	Ser	Val				

10/14

1085	1090	1095
Gly Gly Leu Leu Leu Leu Ala Leu Ile Thr Ala Ala Leu Tyr Lys		
1100	1105	1110
Leu Gly Phe Phe Lys Arg Gln Tyr Lys Asp Met Met Ser Glu Gly		
1115	1120	1125
Gly Pro Pro Gly Ala Glu Pro Gln		
1130	1135	

<210> 9
 <211> 1163
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1) .. (19)
 <223>

<220>
 <221> DOMAIN
 <222> (20) .. (1163)
 <223> mature peptide

<400> 9

Met Thr Arg Thr Arg Ala Ala Leu Leu Leu Phe Thr Ala Leu Ala Thr	-15	-10	-5
Ser Leu Gly Phe Asn Leu Asp Thr Glu Glu Leu Thr Ala Phe Arg Val	-1	5	10
Asp Ser Ala Gly Phe Gly Asp Ser Val Val Gln Tyr Ala Asn Ser Trp	15	20	25
Val Val Val Gly Ala Pro Gln Lys Ile Thr Ala Ala Asn Gln Thr Gly	30	35	40
Gly Leu Tyr Gln Cys Gly Tyr Ser Thr Gly Ala Cys Glu Pro Ile Gly	50	55	60
Leu Gln Val Pro Pro Glu Ala Val Asn Met Ser Leu Gly Leu Ser Leu	65	70	75
Ala Ser Thr Thr Ser Pro Ser Gln Leu Leu Ala Cys Gly Pro Thr Val	80	85	90
His His Glu Cys Gly Arg Asn Met Tyr Leu Thr Gly Leu Cys Phe Leu	95	100	105
Leu Gly Pro Thr Gln Leu Thr Gln Arg Leu Pro Val Ser Arg Gln Glu	110	115	120
Cys Pro Arg Gln Glu Gln Asp Ile Val Phe Leu Ile Asp Gly Ser Gly	130	135	140
Ser Ile Ser Ser Arg Asn Phe Ala Thr Met Met Asn Phe Val Arg Ala	145	150	155
Val Ile Ser Gln Phe Gln Arg Pro Ser Thr Gln Phe Ser Leu Met Gln	160	165	170
Phe Ser Asn Lys Phe Gln Thr His Leu Thr Phe Glu Glu Phe Arg Arg	175	180	185
Thr Ser Asn Pro Leu Ser Leu Leu Ala Ser Val His Gln Leu Gln Gly	190	195	200
Phe Thr Tyr Thr Ala Thr Ala Ile Gln Asn Val Val His Arg Leu Phe	210	215	220
His Ala Ser Tyr Gly Ala Arg Arg Asp Ala Thr Lys Ile Leu Ile Val	225	230	235
Ile Thr Asp Gly Lys Lys Glu Gly Asp Thr Leu Asp Tyr Lys Asp Val	240	245	250
Ile Pro Met Ala Asp Ala Ala Gly Ile Ile Arg Tyr Ala Ile Gly Val	255	260	265
Gly Leu Ala Phe Gln Asn Arg Asn Ser Trp Lys Glu Leu Asn Asp Ile			

11/14

270		275		280		285
Ala Ser Lys Pro	Ser Gln Glu His Ile	Phe Lys Val Glu Asp Phe Asp				
	290	295	300			
Ala Leu Lys Asp	Ile Gln Thr Gln Leu Arg Glu Lys Ile Phe Pro Ile					
	305	310	315			
Glu Gly Thr Glu Thr Thr Ser Ser Ser	Phe Glu Leu Glu Met Ala					
	320	325	330			
Gln Glu Gly Phe Ser Ala Val Phe Thr Pro Asp Gly	Pro Val Leu Gly					
	335	340	345			
Ala Val Gly Ser Phe Thr Trp Ser Gly Gly	Ala Phe Leu Tyr Pro Pro					
	350	355	360			
Asn Met Ser Pro Thr Phe Ile Asn Met Ser	Gln Glu Asn Val Asp Met					
	370	375	380			
Arg Asp Ser Tyr Leu Gly Tyr Ser Thr Glu Leu Ala Leu Trp Lys Gly						
	385	390	395			
Val Gln Ser Leu Val Leu Gly Ala Pro Arg Tyr Gln His Thr Gly Lys						
	400	405	410			
Ala Val Ile Phe Thr Gln Val Ser Arg Gln Trp Arg Met Lys Ala Glu						
	415	420	425			
Val Thr Gly Thr Gln Ile Gly Ser Tyr Phe Gly Pro Ser Leu Cys Ser						
	430	435	440			
Val Asp Val Asp Ser Asp Gly Ser Thr Asp Leu Val Leu Ile Gly Pro						
	450	455	460			
Pro His Tyr Tyr Glu Gln Thr Arg Gly Ala Gln Val Ser Val Cys Pro						
	465	470	475			
Leu Pro Arg Gly Trp Arg Arg Trp Trp Cys Asp Ala Val Leu Tyr Gly						
	480	485	490			
Glu Gln Gly His Pro Trp Gly Arg Phe Gly Ala Ala Leu Thr Val Leu						
	495	500	505			
Gly Asp Val Asn Gly Asp Lys Leu Thr Asp Val Val Ile Gly Ala Pro						
	510	515	520			
Gly Glu Glu Glu Asn Arg Gly Ala Val Tyr Leu Phe His Gly Val Leu						
	530	535	540			
Gly Pro Ser Ile Ser Pro Ser His Ser Gln Arg Ile Ala Gly Ser Gln						
	545	550	555			
Leu Ser Ser Arg Leu Gln Tyr Phe Gly Gln Ala Leu Ser Gly Gly Gln						
	560	565	570			
Asp Leu Thr Gln Asp Gly Leu Val Asp Leu Ala Val Gly Ala Arg Gly						
	575	580	585			
Gln Val Leu Leu Leu Arg Thr Arg Pro Val Leu Trp Val Gly Val Ser						
	590	595	600			
Met Gln Phe Ile Pro Ala Glu Ile Pro Arg Ser Ala Phe Glu Cys Arg						
	610	615	620			
Glu Gln Val Val Ser Glu Gln Thr Leu Val Gln Ser Asn Ile Cys Leu						
	625	630	635			
Tyr Ile Asp Lys Arg Ser Lys Asn Leu Leu Gly Ser Arg Asp Leu Gln						
	640	645	650			
Ser Ser Val Thr Leu Asp Leu Ala Leu Asp Pro Gly Arg Leu Ser Pro						
	655	660	665			
Arg Ala Thr Phe Gln Glu Thr Lys Asn Arg Ser Leu Ser Arg Val Arg						
	670	675	680			
Val Leu Gly Leu Lys Ala His Cys Glu Asn Phe Asn Leu Leu Leu Pro						
	690	695	700			
Ser Cys Val Glu Asp Ser Val Thr Pro Ile Thr Leu Arg Leu Asn Phe						
	705	710	715			
Thr Leu Val Gly Lys Pro Leu Leu Ala Phe Arg Asn Leu Arg Pro Met						
	720	725	730			
Leu Ala Ala Asp Ala Gln Arg Tyr Phe Thr Ala Ser Leu Pro Phe Glu						
	735	740	745			
Lys Asn Cys Gly Ala Asp His Ile Cys Gln Asp Asn Leu Gly Ile Ser						
	750	755	760			
			765			

12/14

```

Phe Ser Phe Pro Gly Leu Lys Ser Leu Leu Val Gly Ser Asn Leu Glu
      770      775      780
Leu Asn Ala Glu Val Met Val Trp Asn Asp Gly Glu Asp Ser Tyr Gly
      785      790      795
Thr Thr Ile Thr Phe Ser His Pro Ala Gly Leu Ser Tyr Arg Tyr Val
      800      805      810
Ala Glu Gly Gln Lys Gln Gly Gln Leu Arg Ser Leu His Leu Thr Cys
      815      820      825
Asp Ser Ala Pro Val Gly Ser Gln Gly Thr Trp Ser Thr Ser Cys Arg
830      835      840      845
Ile Asn His Leu Ile Phe Arg Gly Gly Ala Gln Ile Thr Phe Leu Ala
      850      855      860
Thr Phe Asp Val Ser Pro Lys Ala Val Leu Gly Asp Arg Leu Leu Leu
      865      870      875
Thr Ala Asn Val Ser Ser Glu Asn Asn Thr Pro Arg Thr Ser Lys Thr
      880      885      890
Thr Phe Gln Leu Glu Leu Pro Val Lys Tyr Ala Val Tyr Thr Val Val
      895      900      905
Ser Ser His Glu Gln Phe Thr Lys Tyr Leu Asn Phe Ser Glu Ser Glu
910      915      920      925
Glu Lys Glu Ser His Val Ala Met His Arg Tyr Gln Val Asn Asn Leu
      930      935      940
Gly Gln Arg Asp Leu Pro Val Ser Ile Asn Phe Trp Val Pro Val Glu
      945      950      955
Leu Asn Gln Glu Ala Val Trp Met Asp Val Glu Val Ser Leu Pro Gln
      960      965      970
Asn Pro Ser Leu Arg Cys Ser Ser Glu Lys Ile Ala Gly Pro Ala Ser
      975      980      985
Asp Phe Leu Ala His Ile Gln Lys Asn Pro Val Leu Asp Cys Ser Ile
990      995      1000      1005
Ala Gly Cys Leu Arg Phe Arg Cys Asp Val Pro Ser Phe Ser Val
      1010      1015      1020
Gln Glu Glu Leu Asp Phe Thr Leu Lys Gly Asn Leu Ser Phe Gly
      1025      1030      1035
Trp Val Arg Gln Ile Leu Gln Lys Lys Val Ser Val Val Ser Val
      1040      1045      1050
Ala Glu Ile Thr Phe Asp Thr Ser Val Tyr Ser Gln Leu Pro Gly
      1055      1060      1065
Gln Glu Ala Phe Met Arg Ala Gln Thr Thr Thr Val Leu Glu Lys
      1070      1075      1080
Tyr Lys Val His Asn Pro Thr Pro Leu Ile Val Gly Ser Ser Ile
      1085      1090      1095
Gly Gly Leu Leu Leu Leu Ala Leu Ile Thr Ala Val Leu Tyr Lys
      1100      1105      1110
Val Gly Phe Phe Lys Arg Gln Tyr Lys Glu Met Met Glu Glu Ala
      1115      1120      1125
Asn Gly Gln Ile Ala Pro Glu Asn Gly Thr Gln Thr Pro Ser Pro
      1130      1135      1140
Pro Ser Glu Lys

```

<210> 10
 <211> 769
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)..(22)
 <223>

13/14

<220>

<221> DOMAIN

<222> (23) .. (769)

<223> mature peptide

<400> 10

```


Met Leu Gly Leu Arg Pro Pro Leu Leu Ala Leu Val Gly Leu Leu Ser
-20 -15 -10
Leu Gly Cys Val Leu Ser Gln Glu Cys Thr Lys Phe Lys Val Ser Ser
-5 -1 1 5 10
Cys Arg Glu Cys Ile Glu Ser Gly Pro Gly Cys Thr Trp Cys Gln Lys
15 20 25
Leu Asn Phe Thr Gly Pro Gly Asp Pro Asp Ser Ile Arg Cys Asp Thr
30 35 40
Arg Pro Gln Leu Leu Met Arg Gly Cys Ala Ala Asp Asp Ile Met Asp
45 50 55
Pro Thr Ser Leu Ala Glu Thr Gln Glu Asp His Asn Gly Gly Gln Lys
60 65 70
Gln Leu Ser Pro Gln Lys Val Thr Leu Tyr Leu Arg Pro Gly Gln Ala
75 80 85 90
Ala Ala Phe Asn Val Thr Phe Arg Arg Ala Lys Gly Tyr Pro Ile Asp
95 100 105
Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Leu Asp Asp Leu Arg
110 115 120
Asn Val Lys Lys Leu Gly Gly Asp Leu Leu Arg Ala Leu Asn Glu Ile
125 130 135
Thr Glu Ser Gly Arg Ile Gly Phe Gly Ser Phe Val Asp Lys Thr Val
140 145 150
Leu Pro Phe Val Asn Thr His Pro Asp Lys Leu Arg Asn Pro Cys Pro
155 160 165 170
Asn Lys Glu Lys Glu Cys Gln Pro Pro Phe Ala Phe Arg His Val Leu
175 180 185
Lys Leu Thr Asn Asn Ser Asn Gln Phe Gln Thr Glu Val Gly Lys Gln
190 195 200
Leu Ile Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Leu Asp Ala Met
205 210 215
Met Gln Val Ala Ala Cys Pro Glu Glu Ile Gly Trp Arg Asn Val Thr
220 225 230
Arg Leu Leu Val Phe Ala Thr Asp Asp Gly Phe His Phe Ala Gly Asp
235 240 245 250
Gly Lys Leu Gly Ala Ile Leu Thr Pro Asn Asp Gly Arg Cys His Leu
255 260 265
Glu Asp Asn Leu Tyr Lys Arg Ser Asn Glu Phe Asp Tyr Pro Ser Val
270 275 280
Gly Gln Leu Ala His Lys Leu Ala Glu Asn Asn Ile Gln Pro Ile Phe,
285 290 295
Ala Val Thr Ser Arg Met Val Lys Thr Tyr Glu Lys Leu Thr Glu Ile
300 305 310
Ile Pro Lys Ser Ala Val Gly Glu Leu Ser Glu Asp Ser Ser Asn Val
315 320 325 330
Val His Leu Ile Lys Asn Ala Tyr Asn Lys Leu Ser Ser Arg Val Phe
335 340 345
Leu Asp His Asn Ala Leu Pro Asp Thr Leu Lys Val Thr Tyr Asp Ser
350 355 360
Phe Cys Ser Asn Gly Val Thr His Arg Asn Gln Pro Arg Gly Asp Cys
365 370 375
Asp Gly Val Gln Ile Asn Val Pro Ile Thr Phe Gln Val Lys Val Thr
380 385 390
Ala Thr Glu Cys Ile Gln Glu Gln Ser Phe Val Ile Arg Ala Leu Gly
395 400 405 410
Phe Thr Asp Ile Val Thr Val Gln Val Leu Pro Gln Cys Glu Cys Arg

```

				415					420					425			
Cys	Arg	Asp	Gln	Ser	Arg	Asp	Arg	Ser	Leu	Cys	His	Gly	Lys	Gly	Phe		
			430					435					440				
Leu	Glu	Cys	Gly	Ile	Cys	Arg	Cys	Asp	Thr	Gly	Tyr	Ile	Gly	Lys	Asn		
		445					450					455					
Cys	Glu	Cys	Gln	Thr	Gln	Gly	Arg	Ser	Ser	Gln	Glu	Leu	Glu	Gly	Ser		
	460					465				470							
Cys	Arg	Lys	Asp	Asn	Asn	Ser	Ile	Ile	Cys	Ser	Gly	Leu	Gly	Asp	Cys		
475				480					485						490		
Val	Cys	Gly	Gln	Cys	Leu	Cys	His	Thr	Ser	Asp	Val	Pro	Gly	Lys	Leu		
			495						500					505			
Ile	Tyr	Gly	Gln	Tyr	Cys	Glu	Cys	Asp	Thr	Ile	Asn	Cys	Glu	Arg	Tyr		
		510						515					520				
Asn	Gly	Gln	Val	Cys	Gly	Gly	Pro	Gly	Arg	Gly	Leu	Cys	Phe	Cys	Gly		
		525					530					535					
Lys	Cys	Arg	Cys	His	Pro	Gly	Phe	Glu	Gly	Ser	Ala	Cys	Gln	Cys	Glu		
	540					545					550						
Arg	Thr	Thr	Glu	Gly	Cys	Leu	Asn	Pro	Arg	Arg	Val	Glu	Cys	Ser	Gly		
555					560					565					570		
Arg	Gly	Arg	Cys	Arg	Cys	Asn	Val	Cys	Glu	Cys	His	Ser	Gly	Tyr	Gln		
			575						580					585			
Leu	Pro	Leu	Cys	Gln	Glu	Cys	Pro	Gly	Cys	Pro	Ser	Pro	Cys	Gly	Lys		
			590					595					600				
Tyr	Ile	Ser	Cys	Ala	Glu	Cys	Leu	Lys	Phe	Glu	Lys	Gly	Pro	Phe	Gly		
	605						610					615					
Lys	Asn	Cys	Ser	Ala	Ala	Cys	Pro	Gly	Leu	Gln	Leu	Ser	Asn	Asn	Pro		
	620					625					630						
Val	Lys	Gly	Arg	Thr	Cys	Lys	Glu	Arg	Asp	Ser	Glu	Gly	Cys	Trp	Val		
635					640					645				650			
Ala	Tyr	Thr	Leu	Glu	Gln	Gln	Asp	Gly	Met	Asp	Arg	Tyr	Leu	Ile	Tyr		
			655						660					665			
Val	Asp	Glu	Ser	Arg	Glu	Cys	Val	Ala	Gly	Pro	Asn	Ile	Ala	Ala	Ile		
			670					675					680				
Val	Gly	Gly	Thr	Val	Ala	Gly	Ile	Val	Leu	Ile	Gly	Ile	Leu	Leu	Leu		
	685					690						695					
Val	Ile	Trp	Lys	Ala	Leu	Ile	His	Leu	Ser	Asp	Leu	Arg	Glu	Tyr	Arg		
	700					705						710					
Arg	Phe	Glu	Lys	Glu	Lys	Leu	Lys	Ser	Gln	Trp	Asn	Asn	Asp	Asn	Pro		
715					720					725					730		
Leu	Phe	Lys	Ser	Ala	Thr	Thr	Thr	Val	Met	Asn	Pro	Lys	Phe	Ala	Glu		
				735					740					745			

Ser

Figure 1






Figure 2




Figure 3




Figure 4




Figure 5

